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Abstract 
The rise of antibiotic-resistant microbes, combined with an absence of novel 
antimicrobials in the development pipeline, raises the spectre of a post-antibiotic era and 
has prompted a resurgence of interest in antibiotic discovery and development.  
This project focuses on combining advanced genomics and bioinformatics with 
traditional bioassays and untargeted metabolomics, with the aim to explore the natural 
product repertoire of three Saccharopolyspora strains isolated from the cuticles of the 
Kenyan plant ants, Tetraponera penzigi. The three strains were sequenced using the 
PacBio RSII platform. Bioinformatics suggested the presence of at least 23 biosynthetic 
gene clusters (BGCs) in each strain. Interestingly, several of these are predicted to 
encode novel and uncommon members of chemotypes known to possess potent 
biological activity, including several potential anti-infective agents. We observed that the 
genomes of all three strains encode a cinnamycin-like BGC that proved silent despite 
culturing under a varied range of conditions. The isolate Saccharopolyspora sp. KY21 
proved most tractable under laboratory conditions and was chosen as the basis for 
further study.  
I report the activation of this BGC by expression of two native genes under a constitutive 
promoter, kyaL and kyaR1. kyaL encodes a phosphatidyl ethanolamine methyl 
transferase gene which represents a self-immunity mechanism; resistance – kyaR1 
encodes a pathway specific positive regulator of the SARP family. This led to the isolation 
and characterisation of kyamicin, a novel type B lantibiotic with activity against a range 
of Gram-positive bacteria. Furthermore, I describe the engineering of a platform for 
expression of type B lantibiotics, based on the kyamicin machinery. 
Additionally, I report the discovery of a novel NRPS-derived siderophore via the 
exploitation of untargeted metabolomics data, as well as preliminary attempts to isolate 
an antifungal compound via a bioassay-guided approach. 
Finally, I discuss the biosynthesis of sporeamicin from Saccharopolyspora sp. L53-18, 
an erythromycin-like macrolide antibiotic. 
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1 Introduction 
1.1 Antimicrobial natural products 
Natural products (NPs) are a large group of metabolites that originate from bacteria, 
fungi, plants and some types of animals and have a broad range of functions. Strictly 
speaking NPs include both primary metabolites, which are essential for survival for the 
producer organism, and secondary metabolites, which are extremely specialised and in 
principle dispensable, but more commonly the term NP is reserved to this second type 
of molecules (Katz and Baltz, 2016). These organisms commonly produce NPs to 
establish an advantage in response to specific environmental circumstances, such as 
competition for resources, defence against predators, or as virulence factors in the case 
of pathogenic organisms (Mun et al., 2017, Saha et al., 2016, Baldeweg et al., 2018).  
NP research explores the varied activity of these metabolites, with a focus on those with 
antimicrobial properties (Katz and Baltz, 2016). Antimicrobial describes compounds that 
kill or inhibit the growth of microbes, encompassing both antibiotics and antifungals. 
These are now fundamental to modern medicine, and practices such as orthopaedic 
prosthetic surgeries or transplants would be impossible without them. The rise in 
resistance to antimicrobials has driven the need for novel NPs with new mechanisms of 
action (Martens and Demain, 2017).  
1.1.1 Brief history of antimicrobial NP discovery 
In the beginning of the 20th century, Paul Erhlic coined the term ‘selective toxicity’ and 
introduced the concept of the ‘chemotherapeutic index’ (Krantz, 1974, Ehrlich, 1901). 
This was defined as the minimum effective dose of a given medicine divided by the 
maximum tolerated dose. Ehrlich developed a theory that specific microbes, harmful to 
humans, could be killed without harming the body itself, with the use of a hypothetical 
agent. He named the hypothetical agent Zauberkugel; the magic bullet (Witkop, 1999). 
The first so called magic bullet was Salvarsan, an antimicrobial organoarsenic compound 
developed by Ehrlich in 1909 for the treatment of syphilis. This discovery also led to the 
finding that microorganisms could become resistant to drugs (Kasten, 1996).  
The great revolution in modern medicine and the use of antimicrobials occurred after 
1928, when Sir Alexander Fleming discovered penicillin. Penicillin was the first NP 
antibiotic and it is produced by Penicillium fungi. In the 1930s  Howard Florey and Ernst 
Chain purified penicillin at an industrial scale (Chain et al., 1940) and its structure was 
elucidated in 1949 by Dorothy Hodgkin (Hodgkin, 1949). Around the same time as 
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Fleming’s work, the microbiologist Selman Waksman focused his research on the study 
of soil microorganisms and how they contribute to soil health and fertility. His extensive 
studies concentrated on actinomycetes bacteria (Waksman, 1961) and particularly on 
Streptomyces, which proved to be prolific producers of antibiotics. Waksman’s work 
yielded 20 antibiotics and one in particular, streptomycin (Schatz et al., 1944) was the 
first antibiotic effective against tuberculosis (Waksman et al., 1946), leading to him being 
awarded a Nobel Prize in 1952 . After these major advances, the approach of scaling up 
antibiotic production by fermentation of microorganisms was widely exploited. The 
1940s-1960s were known as the ‘Golden Age’ of antimicrobial discovery, where the 
major classes of antibiotics were discovered and introduced to the clinic (Jones et al., 
2017). This led to a drop in infection-associated mortality and overall increase in life 
expectancy thanks to its help in advancing other areas of medicine. However, the 
antibiotic discovery production line slowed down dramatically at the end of the 1960s. In 
the following decades, only a few novel antibiotics such as the lipopeptide daptomycin, 
have been discovered and approved for clinical use (Laxminarayan, 2014). A timeline of 
antibiotics discovery is presented in Figure 1.1. 
 
 
Figure 1.1: Timeline showing the introduction of new antibiotics and the emergence 
of resistance against them (Clatworthy et al., 2007). Used with permission from Nature 
Chemical Biology. 
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1.1.2 Challenges in antimicrobial NP discovery 
One of the major issues that emerged soon after the ‘Golden Age’ previously described 
was the re-discovery of compounds. It was found that regardless of the location of soil 
sampling and the isolation techniques that followed, screening programs were mostly 
identifying known antibiotics (Baltz, 2006). This forced the introduction of dereplication 
techniques that, relying on mass spectrometry and nuclear magnetic resonance, would 
determine whether the identified compounds were truly novel (Lewis, 2013). Therefore, 
the risk of rediscovery and the need for dereplication imposed a time consuming and 
expensive bottleneck in natural product discovery that still to this day we try to overcome 
with the use of new tools and technologies (Gaudêncio and Pereira, 2015). 
As a result of these obstacles, pharmaceutical companies switched their focus to 
synthetic chemistry for the creation of novel antibiotics. This proved expensive and 
largely unsuccessful, with few antibiotics making it to the clinic. One notable exception 
are the quinolones, which interfere with DNA replication by targeting DNA gyrase and 
are active against Gram-negative and Gram-positive bacteria (Heeb et al., 2011). 
Another approach for the development of antimicrobials is the use of semi-synthetic 
derivatives, as it has been routinely done with the β-lactams, for which we are currently 
between the fourth and fifth generation of derivatives (Page, 2012), or the antibiotics 
clarithromycin and telithromycin, semisynthetic derivatives of erythromycin generated in 
an effort to develop alternatives with improved pharmacokinetic properties (Watanabe et 
al., 1993, Scheinfeld, 2004). Even then, the cost and time required to get a new antibiotic 
to the market have had a negative impact on the discovery and development efforts of 
the big pharmaceutical companies over the last years. As a result, most of their natural 
product departments and screening programs have either been eliminated or 
significantly reduced, further slowing the discovery process (Martens and Demain, 
2017). 
In parallel with this deceleration in antibiotic discovery, bacteria continued to evolve 
under the selective pressure of the extended use and abuse of antibiotics in the clinic 
and in agriculture (Bérdy, 2012, Laxminarayan, 2014). This resulted to the continuous 
increase of resistance, with Gram-negative bacteria tending to be more resistant 
(Fernandes, 2006). Resistance to new antibiotics appeared a short time after their 
introduction into the clinic (Clatworthy et al., 2007), and the emergence of multidrug-
resistant (MDR) and extensively-drug-resistant (XDR) bacteria is currently a serious 
threat for human health even in the developed world (Sherry and Howden, 2018, Martens 
and Demain, 2017, Laxminarayan, 2014). Groups of microorganisms such as the 
5 
 
ESKAPE pathogens (a group of Gram-positive and Gram-negative bacteria responsible 
for life-threatening nosocomial infections with widespread drug resistance mechanisms 
(Santajit and Indrawattana, 2016)) are part of the Global Priority List that the World 
Health Organisation (WHO) has compiled to help prioritize the research and 
development of new antibiotics against the most pressing bacterial threats (Organization, 
2017). 
The expense and difficulty associated with antimicrobial discovery led to a dearth in the 
identification of classes of compounds. Combined with the rapidly rising threat of AMR, 
this has created an urgent need for the discovery of novel NPs, with new modes of action 
to overcome current resistance mechanisms (Lewis, 2013, Santajit and Indrawattana, 
2016).  
 
1.2 Approaches for natural product discovery 
1.2.1 Bioassay-guided discovery 
Perhaps the most traditional method for searching for new antibiotics is bioassay-guided 
discovery. This is based on testing extracts from microbial cultures against bioindicator 
strains to reveal antimicrobial activity. Usually the organism of interest is cultured under 
a range of different media conditions, as compound production is often media dependent. 
If activity is observed, separation and purification techniques are subsequently utilised 
to identify which compound(s) is responsible for the activity. The major drawback of this 
approach is the problem of rediscovery, as discussed above. The chance of finding the 
same compounds from different strains or different locations of sampling is quite high 
and it leads to misdirected efforts (Baltz, 2008, Silver, 2011). 
Despite its limitations, this approach is still widely applied today. Recent examples 
include: the discovery of amycomicin from Amycolatopsis sp. AA4, a highly modified fatty 
acid that inhibits Staphylococcus aureus (Pishchany et al., 2018); a Streptomyces-
derived auxin with activity against phytopathogenic fungi and dermatophytes (Saravana 
Kumar et al., 2018), and six different NPs from the endophytic fungus Emericella sp. 
TJ29 (He et al., 2017). 
1.2.2 Genome mining 
Advances in genomic technologies over the last 20 years have had a great impact on 
the field of NP discovery (Bachmann et al., 2014). In 2001, the first genome sequence 
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of a Streptomyces strain was published: Streptomyces coelicolor A3(2). This revealed 
the presence of more than 20 biosynthetic gene clusters (BGCs) with no known products 
in laboratory conditions (Bentley et al., 2002). These clusters were termed ‘silent’ and 
they represented 75% of the potential NPs encoded by the strain. The subsequent 
sequencing projects of Streptomyces avermitilis (Ikeda et al., 2003) and of 
Saccharopolyspora erythraea NRRL23338  (Oliynyk et al., 2007) gave further insight into 
the untapped biosynthetic potential of even the most well-studied strains. In the years 
that followed, the speed and accuracy of genome sequencing has been rapidly 
accelerated, whereas the cost has decreased dramatically leading to genome 
sequencing becoming a routine laboratory procedure (Gomez-Escribano et al., 2016, 
Loman and Pallen, 2015). As a result, the NCBI genome 
(https://www.ncbi.nlm.nih.gov/genome/) database currently contains more than 160,000 
bacterial genome sequences, 16,000 of which correspond to Actinobacteria.  
The growing availability of genome sequences led to the development of tools with which 
to mine the data and identify biosynthetic gene clusters (BGCs). Tools such as 
antiSMASH (Blin et al., 2017), NaPDoS (Ziemert et al., 2012), GNP/PRISM (Skinnider 
et al., 2015) or BAGEL (van Heel et al., 2018), now allow for the rapid identification and 
annotation of BGCs (Monciardini et al., 2014). The revolution in genome mining enabled 
the acceleration of the NPs discovery pipeline, with the identification of many novel 
families of compounds (Bachmann et al., 2014). The many silent (also known as cryptic) 
BGCs identified encode for secondary metabolites that are often selectively expressed 
in response to very specific stimuli and under strict regulation, due to the high energy 
cost to the bacterial producer, and hence why they are not seen in laboratory conditions 
(Bibb, 2005). The activation of silent BGCs is one of the major goals for NP discovery, 
with expression in heterologous hosts being one of the main techniques employed  
(Rutledge and Challis, 2015, Gomez-Escribano et al., 2016).  
1.2.3 Untargeted metabolomics 
More recently, advances in genomic technologies have been matched with advances 
metabolomic data analysis. Reductions in the costs of processing many samples, along 
with advances in the sensitivity and accuracy of mass spectrometers has given rise to 
untargeted metabolomics approaches. This entails profiling the entire metabolome of 
bacteria or fungi species, commonly analysing a variety of different media and culture 
conditions. Crude extracts are subjected to ultra-performance liquid chromatography 
(UPLC) analysis coupled to spectrometry analyses (MS) (Baltz, 2017). This method 
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follows the OSMAC (One Strain–Many Compounds) approach (Bode et al., 2002) to 
unearth the great metabolic diversity often present in single strains (Senges et al., 2018). 
With untargeted metabolomics, tandem MS/MS data are also analysed and metabolic 
networks can be constructed to provide a deeper understanding of the chemical diversity 
and structural relationships within the detected metabolomes (Chavali et al., 2012, 
Nothias et al., 2018). This allows for rapid identification of NPs, including pathway 
intermediates that might be dismissed in other analyses (Crone et al., 2016, Eyles et al., 
2018, Watrous et al., 2012). All these data can now be deposited in molecular networks 
such as Global Natural Products Social (GNPS) based on the sharing of raw, processed 
or identified tandem mass (MS/MS) spectrometry data (Wang et al., 2016).  
1.2.4 Exploration of rare environmental niches 
As the majority of antimicrobial NPs have been isolated from soil-dwelling 
microorganisms, it has been proposed that, one approach to counter the rediscovery of 
the same antimicrobial compounds is to explore more unusual environmental niches, 
under the reasoning that biological diversity will lead to chemical diversity (Lyddiard et 
al., 2016, Challinor and Bode, 2015). These niches include marine sediments (Jang et 
al., 2013), deserts (Goodfellow et al., 2018), arctic regions (Wietz et al., 2012), and other 
extreme environments (Chen et al., 2014, Molloy and Hertweck, 2017, Simmons et al., 
2008, Yu et al., 2010). One difficulty present both in soil and in any of these cases is that 
the vast majority of environmental bacteria cannot be cultured under laboratory 
conditions and therefore accessing their promising biosynthetic potential is more 
challenging (Rappé and Giovannoni, 2003, Lewis, 2013). 
To overcome this problem, recent advances have been made in the field of culturing 
recalcitrant bacteria. One characteristic example is the work of Yang Bai and colleagues 
where they studied leaf and root microbiota of flowering plants (Bai et al., 2015). They 
combined three bacterial isolation procedures: colony picking from agar plates, limiting 
dilution in liquid media in 96-well microtiter plates and microbial cell sorting. As a result, 
they managed to characterize a total of 21 leaf-derived strains (phyllosphere bacteria) 
although these were undetectable in the culture-independent leaf community profiling. 
Another example of ways to overcome the issue of unculturable bacteria is the Isolation 
chip (or ichip) method of culturing bacteria (Nichols et al., 2010). The ichip cultures 
bacterial species within their soil environment by diluting the soil in agar and nutrients. 
In that way a single cell grows in the ichip's small compartments or wells. The chip is 
wrapped with a semipermeable membrane and is then buried back in the soil to allow 
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interaction with nutrients not available in lab conditions. More than half of the original 
bacterial population can survive by this procedure. The most characteristic example was 
the discovery of the bacteria species Eleftheria terrae, producer of the antibiotic antibiotic 
teixobactin that targets drug-resistant strains like MRSA, in 2015 (Ling et al., 2015). 
One potentially rich source of antimicrobial compounds comes from symbiotic niches. In 
these systems extended coevolution between the symbionts selects for the production 
of compounds that often aid in defence or confer other sorts of advantages that support 
the interaction between organisms  This sort of approach has yielded some interesting 
compounds coming from symbionts of marine organisms such as sponges or bryozoans, 
endophytic bacteria, or microorganisms that form part of insect or even human 
microbiomes (Akbar et al., 2018, Donia et al., 2014). 
1.3 Actinomycetes as prolific producers of natural products 
As it has been mentioned before, almost all antibiotics in clinical use today have been 
isolated from natural sources, mainly from microorganisms (Bérdy, 2012, Newman and 
Cragg, 2016). Among them, the more prolific antimicrobial producers in history are the 
actinomycetes, and it has been estimated that they are the source of around 60% of the 
known bioactive NPs, with around 80% of them being produced by the genus 
Streptomyces (Butler, 2008, Bérdy, 2012). Fungi produce approximately 30% the 
remaining NPs and the rest are made by other types of bacteria. Actinomycetes are 
Gram-positive bacteria with high G-C content and are very diverse morphologically, but 
many are characterised for having hyphal growth that develops in the form of substrate 
and aerial mycelium, and for undergoing a differentiation process that culminates in 
spore formation (Flärdh and Buttner, 2009, Chaudhary et al., 2013). These are 
environmental bacteria that inhabit mainly the soil, although screening studies in novel 
niches as mentioned before has revealed their presence in all sorts of environments, 
including the ocean (Zotchev, 2012) or extreme environments like the Atacama desert 
(Gomez-Escribano et al., 2015). 
Similar to other microorganisms, symbiotic interactions are a promising source of 
antimicrobial producing actinomycetes. One of the best documented cases is that of leaf 
cutter ants, which farm fungi of the Lepiotaceae family that they use as food source and 
engage in a mutualistic relationship with different genus of actinomycetes, mainly 
Streptomyces and Pseudonocardia, which produce antifungal and antibacterial 
compounds that help protect the colony against pathogenic fungi and bacteria (Heine et 
al., 2018). 
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1.3.1 Saccharopolyspora, another talented NP producer genus 
Saccharopolyspora is a genus of bacteria within the family Pseudonocardiaceae, in the 
class of Actinobacteria. The etymology of the genus comes from Saccharum, a generic 
name of sugar cane, and the Greek words ‘polus’ meaning many and ‘spora’ meaning 
seed, or spore. Hence, Saccharopolyspora stands for the many spored organism from 
sugar cane (Lacey and Goodfellow, 1975). It consists of aerobic, high GC content, Gram-
positive species that produce aerial hypha with long chains of spores in spiny spirals 
(Zhou et al., 1998). Saccharopolyspora species have not been as widely studied as other 
actinobacteria and most of the known species have been isolated from diverse sources. 
Based on the taxonomy browser of NCBI, more than 35 Saccharopolyspora species 
have been reported in total. 
This rare actinomycete genus is the source of many unique natural products, Figure 1.2. 
Most notably, the medically and agrochemically important antibiotic erythromycin 
(Oliynyk et al., 2007) and the environmentally benign insecticide spinosyn (Kirst, 2010), 
(Pan et al., 2011). Novel chemistry and biology is associated with other 
Saccharopolyspora species studied in any detail, for example, Saccharopolyspora sp. 
L53-18 produces the novel macrolide antibiotic sporeamicin (Yaginuma et al., 1992) and 
the thermophile Saccharopolyspora rectivirgula is a causative agent of hypersensitivity 
pneumonitis, an inflammatory lung disease (Farmers lung) (Pettersson et al., 2014). 
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Figure 1.2: Structures of NPs isolated from Saccharopolyspora sp.  
Analysis of the BGCs from published Saccharopolyspora species suggest they have the 
capacity to produce many more NPs. Below I outline the main classes of NPs, with a 
focus on those that will be discussed at some point in this thesis.  
1.4 Types of natural products  
1.4.1 Non-ribosomal peptides  
Non-ribosomal peptides (NRPs) are a class of NPs that are synthesized by non-
ribosomal peptide synthetases (NRPSs). NRPSs are large multidomain enzymatic  
complexes that can incorporate and process several hundreds of structurally different 
monomers, including non-proteinogenic amino acids, to give very structurally diverse 
cyclic or linear polypeptides (Marahiel, 2016, Payne et al., 2017, Fischbach and Walsh, 
2006). 
NRPSs have a modular architecture that allows biosynthesis to proceed in an assembly 
line fashion in which each module is in charge of incorporating a new residue to the 
assembled molecule. Therefore, each of these modules consists of a set of core catalytic 
domains that are required for catalysing the activation, incorporation of a specific amino 
acid into the growing peptide chain. The minimum set of domains required for one 
elongation cycle are Adenylation (A), Thiolation or Peptidyl Carrier Protein (T/PCP), and 
Condensation (C) domains (Figure 1.3). 
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Figure 1.3: Illustration of NRP biosynthesis. Aa: amino acid; A: adenylation domain; 
C: condensation domain; PCP: peptidyl carrier protein; and TE: thioesterase domain 
(Desriac et al., 2013) Used with permission from Marine drugs journal. 
 
The peptide assembly is initiated by a loading module, with A and PCP domains only. 
The A domain selects a specific amino acid substrate, activates it with ATP to give an 
amino-acyl adenylate and subsequently tethers it to a phosphopantetheine (PPant) 
prosthetic group on the adjacent PCP via a thioester bond. A domains typically consist 
of 550 aa and the PCP-domain of approximately 80 aa. After the loading module, a 
variable number of elongation modules are in charge of extending the molecule through 
the addition of the aminoacids activated by their A domains. In these modules, the C 
domain (approximately 450 aa) is responsible for the formation of peptide bonds between 
the carboxyl group of the forming peptide and the aa carried by the adjoining module. 
Then the growing peptide chain moves to the following module (Martínez-Núñez and 
López, 2016). Finally, A thioesterase (TE) domain usually present in the last module of 
the NRPS, is responsible for the release of the peptide from the backbone after all the 
required modifications (Fischbach and Walsh, 2006). Other domains that can be a part 
of an NRPS assembly line are: Cyclization (Cy) domains that cyclize peptides into 
thiazoline or oxazolines; Oxidation (Ox) domains that produce thiazoles or oxazoles; 
Reduction (Red) domains that give thiazolidines or oxazolidines; terminal Reduction (R) 
domains to give a terminal aldehyde alcohol; Epimerization (E) domains that produce D-
amino acids and N-methylation (NMT) domains.  
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1.4.1.1 Siderophores 
An example of a type of compound that is commonly (although with some very notable 
exceptions (Carroll and Moore, 2018)) NRPS-derived is siderophores. Siderophores 
(from the Greek: "iron carrier") are molecules that strongly complex metals for absorption 
into microbes (Saxena et al., 1986). Notably, pyochelin is a siderophore of Pseudomonas 
aeruginosa that chelates copper and zinc as well as iron (Brandel et al., 2012). 
Siderophores are synthesized by bacteria and fungi when the availability of the iron is 
low in the environment, as this metal is essential for several cellular processes, such as 
respiration or DNA synthesis. Although iron is extremely abundant in geological terms, 
its bioavailability is seriously limited by the poor solubility of the Fe3+ ion at physiological 
pH. Thus, in many environments its incorporation into the cells requires its solubilization 
and absorption in a chelated form (Saha et al., 2016). Based on the type of the iron ligand 
they contain, NRPS- based siderophores may contain one, two, or three chelating 
oxygen ligands such as hydroxamates (Yamanaka et al., 2005), catecholates (Harris et 
al., 1979), or α‐hydroxycarboxylates (Figure 1.4) (Berti and Thomas, 2009), (Kadi and 
Challis, 2009).  
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Figure 1.4: Structures of siderophores containing different types of ferric‐iron‐
chelating functional groups. Hydroxamate in desferrioxamine E, α‐hydroxycarboxylate 
in achromobactin, catecholate in enterobactin, and nitrogen heterocycle/ phenolate/ 
carboxylate in pyochelin. The atoms that bind to Fe3+ in each structure are highlighted in 
gray. Note: desferroxamine is not synthesised by a NRPS. Used with permission from 
Methods in Enzymology journal (Kadi and Challis, 2009). 
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1.4.1.2 Medically relevant NRPS-derived molecules 
There are numerous NRPS-derived molecules that are medically important and are 
being used successfully to treat numerous infections (Felnagle et al., 2008). 
Characteristically, β-lactams are a large class of antibiotics that come from linear NRPSs. 
They include the penicillins and the cephalosporins that in the beginning of the 20th 
century were one of the main classes of antibiotics prescribed around the world (Elander, 
2003). Another characteristic class is the glycopeptides such as vancomycin, an NRP 
used widely to treat life-threatening infections for patients that have an allergy to β-
lactams. Vancomycin is used against some MRSA infections and other severe infections 
from Corynebacterium and Streptococcus (Nicas and Cooper, 1997). The other clinically 
relevant glycopeptide, teicoplanin, is a semisynthetic antibiotic with a spectrum of activity 
similar to vancomycin and is used in Europe in cases of vancomycin-resistant 
enterococci (Kahne et al., 2005). Finally, lipopeptides, with daptomycin as the main 
representative, are an important member of the NRPs and constitute one of the newest 
classes of antibiotics that was introduced the last 40 years(Huber et al., 1988). 
Daptomycin is used to treat mainly skin infections caused by resistant pathogens 
including MRSA and VRE bacteria (Kirkpatrick et al., 2003). It is worth mentioning the 
cyclosporins (Dreyfuss et al., 1976), a product of linear NRPSs from fungal species that 
have anti-inflammatory and immunosuppressant activity and are being used to prevent 
rejection of organ transplants (Morris, 1984) and for autoimmune diseases (Borel and 
Hiestand, 1999). 
1.4.2 Polyketides  
Polyketides are a very diverse class of molecules generated by the successive 
condensation and modification of short carboxylic acid chains that are activated in the 
form of acyl-CoA extender units. There are several classes of enzymes responsible for 
their biosynthesis, all known as polyketide synthases (PKSs), that can be divided in three 
main groups according to their organisation. Type I PKSs are large, multi-domain 
enzymes with a similar architecture to that of NRPSs in which each module is responsible 
for the addition of a new extender unit (Weissman, 2015). Type II PKSs are composed 
by several monodomain proteins which act iteratively through several rounds of chain 
extension, in order to generate the final molecule (Hertweck et al., 2007). Type III PKS 
on the other hand are homodimers of ketosynthases which catalyze the condensation of 
one or several molecules of extender units in an iterative fashion (Katsuyama and 
Ohnishi, 2012). 
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The modules of type I PKS and the minimal module of type II PKSs catalyse the addition 
and a-/b-carbon modification of an extender unit to the growing PK chain (Minowa et al., 
2007). PKSs catalyse decarboxylative Claisen-like thioester condensation reactions to 
connect the extender units together (Staunton and Weissman, 2001). The minimum set 
of domains required for chain elongation are an acyltransferase (AT), an acyl carrier 
protein (ACP) and a ketosynthase (KS) domain. ATs select an extender malonyl-CoA 
unit that gets transferred onto the PPant group of the ACP domain, via a covalent 
thioester bond. Similar to the NRPS biosynthesis, type I PKSs start with a loading module 
consisting of an AT and ACP domain that incorporate a starter unit. The following 
modules contain a KS domain that receives the growing PK chain and catalyses its 
condensation with the acyl extender group loaded by the AT domain and attached to the 
ACP domain in that same module (Weissman, 2015). Further modifications at the PK 
chain can be catalysed by accessory domains such as ketoreductase (KR), dehydratase 
(DH), enoyl reductase (ER) and C-methyltransferase (MT). Typically, a TE releases the 
PK chain from the PKS assembly line. A hypothetical PKS assembly line is presented in 
Figure 1.5. 
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Figure 1.5: Illustration of PKS assembly line biosynthesis. (a) PK modular chain 
elongation on a hypothetical assembly line (b) The Claisen condensation catalysed 
during PKS biosynthesis. A C–C bond formation occurs between two esters or an ester 
and another carbonyl compound in the presence of a strong base, resulting in a β-keto 
ester or a β-diketone. Decarboxylation of the downstream (methyl)malonyl-S-ACP yields 
a nucleophilic thioester enolate, which attacks the upstream acyl-S-ACP thioester to form 
a C-C bond. (c) β-Carbon processing. The product of the α-ketoacyl-S-T condensation 
is reduced by the KR domain to form a β-hydroxyacyl-S-T and is dehydrated by the DH 
domain. This reaction yields an β-enoyl-S-T and reduction of this species by the ER 
domain results in a fully saturated acyl-S-T. Adapted from Scott (2017) and reproduced 
here with permission.  
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1.4.2.1 Erythromycin  
The type I PKS macrolide antibiotic erythromycin was first isolated from the actinomycete 
Saccharopolyspora erythraea (formerly Streptomyces erythreus) and was used in the 
clinic as early as 1952 (Haight and Finland, 1952). Erythromycin A is a member of 
macrolide family of compounds, which are characterized by big macrocyclic lactone rings 
that can be 14, 15, or 16 membered (Zhang et al., 2008). It is used in clinical medicine 
against infections caused by gram-positive bacteria and also for many pulmonary 
infections, such as Legionnaire’s disease and as an alternative for patients allergic to 
penicillins (Staunton and Wilkinson, 1997). Erythromycin also acts as agonist of the 
motilin receptor and a semi-synthetic derivative is under development as a potential 
treatment for gastric motility disorder (Butler, 2008). 
 As illustrated in Figure 1.6, erythromycin is derived from a PKS named 6-
deoxyerythronolide B synthetase (DEBS). This PKS is split in three different proteins,  
DEBS 1, DEBS 2, and DEBS 3 (Caffrey et al., 1992), encoded by genes designated as. 
eryAI, eryAII, and eryAIII respectively. Each DEBS protein contains two modules and 
each module has domains that encode for an AT, ACP, and KS. Module four contains a 
DH, ER and KR domain. The TE domain in module six releases the aglycon product of 
DEBS 3, which is cyclized and gives 6-deoxyerythronolide B (DEB). Additional tailoring 
steps result in the production of erythromycin A. 
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Figure 1.6: Biosynthesis of erythromycin A. Three ORFs designated for the 
biosynthesis of erythromycin: eryAI, eryAII, and eryAIII. B. 6-deoxyerythronolide B 
synthetase (DEBS) consists of three proteins DEBS 1, DEBS 2, and DEBS 3, encoded 
by A. C. Modules of each DEBS protein. D. Cyclization and release step leads to 6-
deoxyerythronolide B (DEB). E. Additional tailoring steps produce Erythromycin. 
Reproduced with permission from Microbiology and molecular biology reviews (Bender 
et al., 1999). 
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1.4.3 Ribosomally synthesised and post-translationally modified peptides  
Ribosomally synthesised and post-translationally modified peptides (RIPPs) are NP 
originated from peptides that are encoded by small structural genes. Despite their 
proteinogenic nature, these compounds exhibit a great structural diversity thanks to the 
extensive and varied modifications they undergo (Skinnider et al., 2016, Hudson and 
Mitchell, 2018). The full-length product of the RiPP structural genes is usually 
denominated precursor peptide and designated as “A”, while the gene encoding it is 
designated as lanA (Arnison et al., 2013). This precursor peptide has two parts, the core 
peptide, which is the part of the peptide that constitutes the final product and is the 
substrate for the posttranslational modifications, and the leader peptide, that usually 
precedes the core. The leader peptide does not form part of the final molecule and it is 
cleaved at some point during RiPP maturation (Figure 1.7). This leader peptide often has 
recognition domains where the tailoring enzymes bind to modify the core peptide. In most 
cases it is not clear whether the cleavage happens right at the end of the pathway or 
earlier in the process and is a characteristic that varies between RiPPs (Arnison et al., 
2013). 
 
 
Figure 1.7: General biosynthetic pathway for RiPPs (Arnison et al., 2013). 
Reproduced with permission of the Royal Society of Chemistry. 
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1.4.3.1 Lantibiotics 
Lantibiotics are a group of RiPPs characterized by the presence of lanthionine type 
thioester bonds which crosslink specific amino acid side-chains of the core peptide. 
Lantibiotics are produced by many Gram-positive bacteria such as lactic acid bacteria, 
Bacillus, Enterococcus and actinomycetes, among others (Cooper et al., 2010), (Figure 
1.8), and their biosynthesis requires extensive posttranslational modifications (Nagao, 
2009). Based on the structure and the antimicrobial properties, lantibiotics can be 
subdivided into type A & B. 
Type-A lantibiotics include molecules such as nisin (Shin et al., 2016), subtilin (Banerjee 
and Hansen, 1988) and gallidermin (Kellner et al., 1988). They are elongated peptides 
up to 34 residues in length and their lanthionine bridges are arranged in a similar way 
(Figure 1.8). Type-B lantibiotics include related molecules, such as cinnamycin, 
duramycin & ancovenin and they are globular peptides, up to 19 residues long. They 
disrupt enzymatic function, such as inhibition of the cell wall biosynthesis (McAuliffe et 
al., 2001). Their mode of action is based on the disruption of the membrane integrity of 
their target (Chatterjee et al., 2005). 
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Figure 1.8: Structures of known lantibiotics. Reproduced with permission from 
Chemical Reviews (Chatterjee et al., 2005). 
 
The first type B lantibiotic to be characterised was cinnamycin from Streptomyces 
cinnamoneus DSM 40646 (Figure 1.9). It is active against a broad range of gram-positive 
bacteria, primarily against Bacilus subtilis. Cinnamycin acts by binding to the membrane 
amino phospholipid, phosphatidylethanolamine (PE). This induces transbilayer lipid 
movement (TLM) which compromises the structural integrity of the membrane leading to 
cell lysis (Hullin-Matsuda et al., 2016). This mechanism is unique to the cinnamycin 
family of lantibiotics (Widdick et al., 2003). 
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Figure 1.9: Profile of Cinnamycin A. Cinnamycin structure. B. Scanning electron 
micrograph of S. cinnamoneus. C. Structure of PE. Reproduced with permission from 
Journal of industrial microbiology & biotechnology (O’Rourke et al., 2017). 
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Duramycin is closely related to cinnamycin, and they differ by a single amino acid in 
position 2: arginine for cinnamycin and lysine for duramycin. Duramycin is a NP produced 
by various streptomycetes such as Streptomyces cinnamoneus ATCC 12686. 
Duramycin was recently reported to effectively block TIM1, a cofactor associated with 
the ZIKV (Zika virus) infection in primary placental cells and chorionic villus explants. 
This is of great interest since it suggests a possible medical application to blocking the 
virus to infect the foetus through the mother (Tabata et al., 2016). Additionally, duramycin 
is in phase II clinical trials for the treatment of cystic fibrosis (Oliynyk et al., 2010).  
1.4.3.1.1 Biosynthesis 
Lantibiotics undergo post translational modifications of specific amino acids inside the 
cell, get transported across the cytoplasmic membrane and there, the leader peptides 
are cleaved to release the mature peptide that has a specific activity (McAuliffe et al., 
2001). Lanthionine bridges are composed of two alanine residues that are crosslinked 
on their β-carbon atoms by a thioether link (Figure 1.10). Thioether links are formed first 
by a dehydration of T4, T11, T18 and S6 by LanM to form dehydrobutyrine (Dhb) and 
dehydroalanine (Dha) residues, respectively. After thioether cyclization by LanM, Dhb 
becomes S-linked Abu and Dha becomes S-linked Ala. D15 is hydroxylated by LanX and 
the lysinoalanine bridge is formed between Dha6 and K19 catalysed by LanN.  After the 
core peptide is fully modified, the leader peptide is cleaved proteolytically to yield the 
mature lantibiotic. 
 
 
Figure 1.10: General biosynthetic scheme of thioether linkage in lanthipeptides.       
R = H, Me; Xn = amino acids. Reproduced with permission from Appl Environ Microbiol 
journal (Chen et al., 2017). 
 
1.4.3.1.2 Regulation 
The genes involved in the regulation of lantibiotics are presented in Table 1.1, proposed 
by cinnamycin and duramycin regulation. In detail, lanA encodes for the precursor 
peptide, lanM is the lanthionine synthetase that introduces the lanthionine and methyl-
lanthionine bridges, lanN encodes the formation of lysinoalanine bridge, lanX is  a 
hydroxylase that modifies D15, lanTH encodes an ABC transporter involved in the export 
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of the lantibiotic, lanKR encodes a two-component regulatory system of unknown 
function, lanL encodes  immunity and lanR1 the activator of the putative operon encoding 
the lantibiotic biosynthetic machinery (O’Rourke et al., 2017, An et al., 2018). 
 
Table 1.1: Proteins encoded by lantibiotics BGCs. 
Lantiobiotic Proposed 
Function 
LanA Precursor peptide 
LanN Formation of 
lysinoalanine bridge 
LanM Formation of 
lanthionine residues 
LanX Hydroxylation of 
D15 
LanT Export 
LanH Export 
LanR Regulation 
LanK Regulation 
LanL Immunity 
LanR1 Regulation 
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1.5 Project Objectives 
This project will explore the diversity and biological activity of new NPs produced by 
underexploited Saccharopolyspora species, including new strains isolated from fungus-
growing ant colonies. 
Firstly, I investigate three Saccharopolyspora sp. strains named KY, from Tetraponera 
penzigi fungus farming ants. All three strains, KY3, KY7 and KY21 were isolated from 
bacteria from the ants located in the domatia, hollow swellings at base of thorns of acacia 
trees in Kenya. By using a tripartite approach that combines genomic, untargeted 
metabolomic and bioassay data, the diversity of the NP capacity of the strains is 
presented.  
Also, I investigate a known Saccharopolyspora strain, the producer of sporeamicin, a 14-
membered erythromycin-like antibiotic. The aim of this part of the project is to identify 
new enzymes and mechanisms that lead to the biosynthesis of sporeamicin. 
Overall this project aims to: 
1. Use genome mining approaches to identify putative silent BGCs of interest in KY 
strains and express them. 
2. Explore the potential of engineering a platform to express type B lantibiotics. 
3. Identify novel compounds by untargeted metabolomics and bioassay data and 
match them to a genetic context. 
4. Investigate the biosynthesis of sporeamicin and identify novel enzymes. 
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2 Materials and Methods 
2.1 Lab supplies 
All reagents were obtained from commercial suppliers (Sigma Aldrich and Alfa Aesar, 
BD Biosciences) and were used without further purification. Solvents were obtained from 
Fisher Scientific in HPLC grade. A list of commercially available enzymes, kits, reagents 
and size markers for DNA used are in shown in Table 2.1. 
 
Table 2.1: Lab supplies used in this work 
Suppliers Enzymes and kits 
GE Healthcare Life Sciences Whatman Grade AA discs 
New England Biolabs 1 kb and 2-log DNA ladders 
Gibson Assembly® Master Mix 
Q5® High-Fidelity DNA polymerase 
T4 DNA ligase 
MP Biomedicals FastDNA™ SPIN KIT 
Promega, Southampton GoTaq® G2 Green Master Mix 
Roche Deoxynucleoside Triphosphate (dNTPs) 
Set PCR Grade 
rAPid Alkaline Phosphatase 
Qiagen QIAquick® Gel Extraction Kit 
QIAquick® PCR Purification Kit 
QIAprep® Spin Miniprep Kit 
 
2.2 Bacterial strains, growth conditions, plasmids and primers 
2.2.1 Bacterial strains and growth conditions 
All Saccharopolyspora strains were grown on SF+M medium with appropriate antibiotics 
at 30°C. All E. coli and bioindicator strains were grown at LB medium with appropriate 
antibiotics at 37°C, unless stated differently. The strains are listed in Table 2.2. The 
bioindicator strains used in bioassays in this study are listed in Table 2.3. 
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Table 2.2: Strains used in this work 
Strain Description Reference 
E. coli ATCC 25922 Bioassay strain; WT ATCC, USA 
 
 
E. coli DH5α 
Cloning strain; Fˉ, endA1, glnV44, 
thi-1, recA1, relA1, gyrA96, deoR,  
nupG, ϕ80dlacΔ(lacZ)M15, 
Δ(lacIZYA-argF)U169, hsdR17(rK- 
mK+), λ– 
Hanahan, 1983 
 
E. coli ET12567/pUZ8002 
E. coli ET12567 containing plasmid 
pUZ8002, a not self-transmissible 
plasmid which can mobilize other 
plasmids 
Mc Neil et al, 
1992; Flett, 1997 
Saccharopolyspora sp. 
KY3 
Strain from the cuticles of 
Tetraponera penzigi 
This work 
Saccharopolyspora sp. 
KY7 
Strain from the cuticles of 
Tetraponera penzigi 
This work 
Saccharopolyspora sp. 
KY21 
Strain from the cuticles of 
Tetraponera penzigi 
This work 
Saccharopolyspora sp. 
L53-18/ FERM BP-2231 
Producer of sporeamicin Yaginuma, S. et 
al., 1992 
Streptomyces 
cinnamoneus DSM 40005 
Producer of cinnamycin DSMZ, 
Germany 
Streptomyces coelicolor 
M1152 
antibiotic producing superhost 
[ΔactΔred Δcpk Δcda 
rpoB(C1298T)] 
Escribano et al, 
2011 
Streptomyces coelicolor 
M1152/pWDW63 
M1152 carrying the biosynthetic 
genes for kyamicin 
This work 
Streptomyces coelicolor 
M1152/pEVK6 
M1152 carrying pIJ10257/R1L This work 
Streptomyces coelicolor 
M1152/pEVK7 
M1152 carrying pIJ10257/LR1 This work 
Streptomyces coelicolor 
M1152/pWDW63/pEVK6 
M1152 carrying the biosynthetic 
genes for kyamicin plus 
pIJ10257/R1L 
This work 
Streptomyces coelicolor 
M1152/pWDW63/pEVK7 
M1152 carrying the biosynthetic 
genes for kyamicin plus 
pIJ10257/LR1 
This work 
Streptomyces coelicolor 
M1152/pEVK6/pWDW70 
M1152 carrying pIJ10257/R1L & 
pWDW70 
This work 
Streptomyces coelicolor 
M1152/pEVK6/pEVK10 
M1152 carrying pIJ10257/R1L & 
pWDW70 carrying the synthetic 
kyamicin core peptide 
This work 
 
  
29 
 
Table 2.3: Bioassay strains used in this study 
Bioassay strains Description/Genotype Reference 
Enterococcus faecium 
6295 (VRE) 
Clinical Isolate from Norfolk and 
Norwich University Hospital. 
Professor Andrew Hart, Dr Catherine 
Tremlett and Ashleigh Crane. 
NNUH 
Bacillus subtilis ESKAPE ESKAPE strain Handelsman lab 
Staphylococcus aureus 
(MRSA) 
Clinical Isolate from Dr Justin 
O'Grady. 
UEA Medical 
School 
Staphylococcus 
epidermidis 
ESKAPE strain, 14990TM ATCC, USA 
Bacillus subtilis EC1524 Bioassay strain; trpC2, Subtilin BGC 
deleted 
Widdick et al., 
2003 
Streptomyces antibioticus, 
TU1798  
Gram-positive bioassay strain Tübingen 
Candida albicans CA-6 opportunistic pathogenic yeast Maconi et 
al.,1976 
 
2.2.2 Vectors 
Plasmids used and constructed in this study are listed in Table 2.4. 
Table 2.4: Plasmids used in this work 
Plasmid Genotype/description Reference 
pGP9 pSET152-derived φBT-based integrative 
expression vector 
Gregory et al., 
2003 
pSET152 ϕC31 attP-conjugative vector Gregory et al., 
2003 
pOSV556t integrative plasmid, ermE* promoter  Sydor et al., 2012 
pIJ10257 oriT, φBT1 attB-int, Hygr, ermEp* Hong et al., 2005 
pKC1132 conjugative suicide vector Bierman et al., 
1992 
pEVK1 pUC57/pR1L 1 GenScript™ 
pEVK2 pUC57/pLR1 1 GenScript™ 
pEVK3 pUC57/KY3  GenScript™ 
pEVK4 pGP9/R1L This work 
pEVK5 pGP9/LR1 This work 
pEVK6 pIJ10257/R1L This work 
pEVK7 pIJ10257/LR1 This work 
pEVK10 pWDW70/KYA 4 This work 
pADW11 pOSV55t based vector with a pSAM2 integrase and 
and an ermE* promoter. It carries a thiostrepton 
resistance gene for selection in Streptomyces and 
a carbenicillin resistance gene for E. coli 
This work 
pADW19 Same as pADW11 but with additional 
ermE*p::kyaR1  and the kyaN promoter  
This work 
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pWDW60   pUC57/KY3 based lantibiotic biosynthetic cluster 
subcloned EcoRI/XbaI into pBlueScriptIIKS cut the 
same. This was made because I think there is a 
concatenation of at least two copies of the cluster 
in the GenScript construct that has been causing 
trouble with Redirect. 
This work 
pWDW63 pSET152/KY3. KY3 stands for set of biosynthetic 
genes of kyamicin BGC 
This work 
pWDW55 pUC57/KY3 lantibiotic biosynthetic cluster 
transformed into BW25113pIJ790 and targeted 
with a cinA replacement cassette generated from 
pIJ10700 (hyg) using the following primers 
This work 
pWDW59 pWDW55, carrying the KY3 lantibiotic with cinA 
replaced with a cassette generated from pIJ10700 
(hyg), transformed into DH5αBT340 and grown at 
42C so that the cassette is flipped out and replaced 
by a SCAR.  
This work 
pWDW61 kyaA generated by PCR using the GenScript 
plasmid as template and Q5 polymerase  
This work 
pWDW65 The EcoR1/KpnI fragment of pWDW59 cloned into 
the vector fragment of EcoRI/KpnI cut pWDW64 to 
reconstitute the biosynthetic gene cluster but with 
kyaA replaced with a scar. 
This work 
pWDW66 pADW19 with kyaA and thiostrepton resistance 
genes, under the control of kyaN promoter 
This work 
pWDW68 A PCR covering the leader peptide and upstream 
region of the GenScript Biosynthetic cluster in 
pWDW60 cut with EcoRI/KpnI and cloned into 
pBSIIKS 
This work 
pWDW69 A PCR covering the downstream region from the 
end of the leader peptide of the GenScript 
Biosynthetic cluster in pWDW60 cut with StuI/KpnI 
and cloned into pWDW68 also cut StuI/KpnI.  
This work 
pWDW70 The EcoRI/KpnI fragment from pWDW69 carrying 
the 5’ end of the kyamicin cluster was cloned into 
the vector portion of a EcoRI/KpnI digested 
pWDW63. This restores most of the cluster but the 
kyaA propeptide region has been replaced with a 
StuI site.  
This work 
 
2.2.3 Primers 
The primers used in this study are presented in Appendix 1. 
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2.3 Culture and production media 
2.3.1 Culture media 
Instant Mash Agar (IMA) for sporulation of Actinomycetes 
SMASH  20.0 g 
Agar 20.0 g 
Tap water to 1 L 
 
SNA  
Difco Nutrient Broth 8.0 g 
Formedium 7.0 g 
Distilled water to 1 L 
 
SF+M for growth and conjugation of actinomycetes 
Soya flour 20.0 g 
Mannitol 20.0 g 
Lab M No 1 agar 20.0 g 
Tap water to 1 L 
 
SV2 for seed cultures and for production of mycelia 
Glucose  15.0 g 
100% Glycerol solution  15.0 g  
Soy Peptone  15.0 g 
NaCl 3.0 g 
CaCO3 1.0 g 
 
Yeast Extract-Malt Extract (YEME) for growth of Saccharopolyspora sp. L53-18 
(Yaginuma et al., 1992) 
 
Yeast extract 3.0 g 
Bacto-peptone 5.0 g 
Malt extract 3.0 g 
Glucose 10.0 g 
Sucrose 340.0 g  
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Distilled water to 1 L 
For YEME agar addition of 15 g Difco Bacto agar 
After autoclaving, addition of MgCl2·6H2O to a 5 mM final concentration  
 
2.3.2 Production media 
All the SM Media protocols were provided from GlaxoSmithKline (formerly Glaxo 
Wellcome) and they are generally screening media for metabolite production in 
actinomycetes. 
ERY-P Medium Suggested for production of Erythromycin 
Glucose 50.0 g  
Soy flour 30.0 g 
Ammonium sulphate 3.0 g 
Sodium chloride 5.0 g 
Calcium carbonate 6.0 g 
Distilled water to 1 L 
Adjust pH to 7.0 
 
R5 for all overlay bioassays 
Sucrose 103.0 g 
K2SO4 0.25 g 
MgCl2 · 6H2O 10.12 g 
Glucose  10.0 g 
Casamino acid  0.1 g 
Yeast Extract  5.0 g 
TES 5.73 g 
Trace elements solution  2.0 mL 
Distilled water to 1 L 
Adjust to pH 7.0 with 5M NaOH 
 
For solid medium this was dispensed in 95 mL aliquots and add 22 g of Difco Bacto Agar 
(Becton & Dickinson 214030) 
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Trace Elements for R5 
ZnCl2 0.04 g 
FeCl2 · 6H2O 0.2 g 
CuCl2 · 2H2O 0.01 g 
MnCl2 · 4H2O 0.01 g 
Na2B407 · 10H2O 0.01 g 
(NH4)6Mo7O24 · 4H2O 0.01 g 
 
SM3 
Glucose 5.0 g 
MD30E Maltodextrin 50.0 g 
Arkasoy soya flour 25.0 g 
Molasses (beet)  3.0 g 
K2HPO4 0.25 g 
CaCO3  2.5 g 
Distilled water to 1 L 
Adjust pH to 7.0 with KOH 
 
SM5 
Peptone (Oxoid L34)  20.0 g 
Lab Lemco (Oxoid L29)  8.0 g 
Glucose 15.0 g 
Glycerol soln. 10.0 g 
CaCO3 0.4 g 
Distilled water to 1 L 
Adjust pH to 7.2 with KOH 
 
SM6 
Corn Steep Liquor 40.0 g 
MD30E Maltodextrin 20.0 g 
NaCl 2.5 g 
MgSO4 0.5 g 
Tap water to 1 L 
Adjust pH to 7.0 with KOH 
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SM7 
MOPS 20.9 g 
L-Proline 15.0 g 
Glycerol soln. 20.0 g 
Sucrose 2.5 g 
L-Glutamate 1.5 g 
NaCl 0.5 g 
K2HPO4 2.0 g 
*0.2M MgSO4 10.0 mL 
*0.02 M CaCl2 10.0 mL 
*Trace salts No. 1 (CAB) 5.0 mL 
*NOTE to be added pre-autoclaving 
Distilled water to 1 L 
Adjust pH to 6.5 with KOH 
 
SM12 
Arkasoy soya flour 10.0 g 
Glucose 50.0 g 
Peptone (Oxoid L34) 4.0 g 
Lab Lemco (Oxoid) 4.0 g 
Yeast Extract (Oxoid) 1.0 g 
NaCl 2.5 g 
CaCO3 5.0 g 
Tap water to 1 L 
Adjust pH to 7.6 with KOH 
 
SM14 
Glucose 10.0 g 
Soy Peptone (Lab M) 20.0 g 
Lab Lemco (Oxoid) 5.0 g 
NaCl 5.0 g 
ZnSO4 · 7H2O 0.01 g 
Distilled water to 1 L 
Adjust pH to 7.0 with KOH 
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SM15 
MOPS 20.9 g 
Casamino acids 11.5 g 
Glycerol soln. 23.0 g 
NaCl 0.5 g 
K2HPO4 0.52 g 
EDTA 0.25 g 
*MgSO4 · 7H2O 0.49 g 
*CaCl2 · 2H2O 0.029 g 
*Trace salts No.1 5.0 mL 
*added pre-autoclaving 
Distilled water to 1 L 
Adjust pH to 6.5 with KOH 
 
SM18 
Glucose 15.0 g 
Soluble starch (BDH) 40.0 g 
Pharmedia 25.0 g 
Molasses (beet) 20.0 g 
CaCO3 8.0 g 
Tap water to 1 L 
Natural pH 7.2 pre-sterilisation 
 
SM19 
Tomato paste 40.0 g 
Oat flour (Avenaflo) 15.0 g 
Glucose 2.0 g 
Tap water to 1 L 
Natural pH 6.0 pre-sterilisation 
 
SM20 
Maltose 20.0 g 
Peptone (Oxoid L37) 5.0 g 
Lab Lemco (Oxoid) 5.0 g 
Yeast extract (Oxoid) 3.0 g 
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NaCl 3.0 g 
MgSO4 · 7H2O 1.0 g 
Tap water to 1 L 
Natural pH 7.2 pre-sterilisation 
 
SM25 
Peptone (Oxoid L34) 10.0 g 
Malt extract (Oxoid) 21.0 g 
Glycerol soln. 40.0 g 
Distilled water to 1 L 
Natural pH 6.3-6.5 
After autoclaving pH is 6.3 
 
SM30 
Tomato paste 40.0 g 
Oat flour (Avenaflo) 15.0 g 
Glucose 2.0 g 
Tap water to 1 L 
Adjust pH to 4.5 with HCl 
 
SM32 
Peptone (Oxoid L34) 10.0 g 
Malt extract (Oxoid) 21.0 g 
Glycerol soln. 40.0 g 
Distilled water to 1 L 
Adjust pH to 4.5 with HCl 
 
Sporeamicin seed medium for Saccharopolyspora sp. L53-18 (Yaginuma et al., 1992) 
Glucose 10.0 g 
Dextrin 10.0 g 
Yeast extract 5.0 g 
Casein hydrolysate 5.0 g 
Calcium carbonate 1.0 g 
Tap water to 1 L 
Adjust pH to 6.5 
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Sporeamicin production medium for production of sporeamicin (Yaginuma et al., 
1992) 
Glucose 30.0 g 
Corn steep liquor 10.0 g 
Dry yeast 6.0 g  
Cobalt chloride 0.1 g 
Tap water to 1 L 
Adjust pH to 7 
 
2.4 Molecular biology methods 
2.4.1 Saccharopolyspora genomic DNA preparation 
Saccharopolyspora cultures were prepared by inoculating spores in 50 mL SV2 in 250 
mL Erlenmeyer flask and subsequently grown for 3 days at 30°C (or until sufficient 
mycelium was observed).  When the use of genomic DNA was for PCR applications, the 
isolation was performed by using the FastDNA™ SPIN KIT, (MP Biomedicals). High 
quality genomic DNA for sequencing was isolated by the salting-out procedure. 
 Salting out procedure for the isolation of genomic DNA 
50 mL cultures were pelleted at 4000 g for 5 min, the supernatant was removed, and the 
mycelium was divided in 15 mL falcon tubes. The mycelium was resuspended in 10 mL 
of 10.3% sucrose solution and pelleted at 4000 rpm for 5 min. It was again resuspended 
in 5 mL SET buffer. 200 μL of lysozyme solution were added and subsequently 40 μL of 
RNAse ONE™ solution. The mix was incubated at 37°C at 125 rpm for 1 h. After 1 h, 
extra 100 μL of lysozyme were added and repeated if needed, until lysis was complete. 
140 μL of proteinase K solution was added, mixed and 300 μL of SDS 20% was added, 
mixed by inversion and the mixture was incubated for 1 h at 55°C, with occasional 
inversion. Then 2 mL 5M NaCl were added and it was mixed by inversion, before letting 
to cool down to 37°C. Subsequently, 6 mL of chloroform were added with a glass pipette 
at the mixture, mixed by inversion for 30 min at 20°C. The mixture was pelleted at 4500 
g for 15 min at 20°C. The supernatant was transferred to 4 falcon tubes and isopropanol 
was added up to 13 mL and mixed by inversion. After 3 min the aggregated DNA was 
spooled with a crooked glass pipette and transferred to a sterile microcentrifuge tube 
with 1 mL of 70% ethanol. DNA was store in -4°C till further use. When dried for use, 
DNA was stored in 1 mL TE buffer. 
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2.4.2 Polymerase chain reaction (PCR) 
PCR reactions were performed in a T100™ Thermal Cycler (Bio-Rad). The general 
protocol for 50 μL reaction and the PCR conditions are presented (Table 2.5). The 
general protocol for colony PCR with the GoTaq master mix is presents at Table 2.6. 
Table 2.5: Protocol for 50 μL Q5 PCR reaction  
Component 50 µL reaction Final Concentration 
5X Q5 Reaction Buffer 10 µL 1X 
10 mM dNTPs 1 µL 200 µM 
10 µM Forward Primer 2.5 µL 0.5 µM 
10 µM Reverse Primer 2.5 µL 0.5 µM 
Template DNA variable < 1,000 ng 
Q5 High-Fidelity DNA 
Polymerase 
0.5 µL 0.02 U/µL 
5X Q5 High GC Enhancer 10 µL 1X 
Nuclease-Free Water to 50 µL  
 
Step Temperature [°C] Time Repeat (×) 
Initial denaturation 98 3 min 1 
Denaturation 98 30 s 
30 Annealing 50-72 30 s  
Elongation 72 45 s/kb 
Final elongation 72 7 min 1 
Hold 12 ∞ 1 
 
Table 2.6: Protocol for 50 μL Colony GoTaq PCR reaction 
Component 25 µL reaction Final Concentration 
2X GoTaq Green PCR Mix 12.5 µL 1X 
10 µM Forward Primer 0.5 µL 0.5 µM 
10 µM Reverse Primer 0.5 µL 0.5 µM 
Template DNA variable < 250 ng 
Nuclease-Free Water to 25 µL  
 
Step Temperature [°C] Time Repeat (×) 
Initial denaturation 95 5 min 1 
Denaturation 95 30 s 
30 Annealing 50-72 30 s  
Elongation 72 45 s/kb 
Final elongation 72 7 min 1 
Hold 12 ∞ 1 
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2.4.3 Agarose gel electrophoresis 
Agarose gels were prepared by adding agarose to TBE buffer to a final concentration 
between 0.8 and 1.0%, depending on the size of DNA fragments for analysis. 10 μg/mL 
ethidium bromide and DNA were prepared by addition of loading dye before applying it 
to the gel. 1 kb or 2-log ladders (NEB) was applied on the gel. Gel electrophoresis was 
performed in TBE buffer using a PowerPac™ Universal Power Supply (Bio-Rad) run 
between 80-120 V, until separation of DNA fragments. A UV Transilluminator and Gel 
Documentation System (UVP) was used to visualise the samples ran on the gel.  
2.4.4 Cloning 
Standard molecular biology procedures were applied. DNA fragments were cut with the 
appropriate restriction endonucleases in 50 μL reaction volumes and incubated at 37°C 
for 2 h. 1 μL of alkaline phosphatase (AP) was added along with 6 μL of AP buffer and 3 
μL ddH2O and incubated for a further 60 min at 37°C. Digests were purified by 0.8-1.0% 
agarose gel electrophoresis. Purified digest products were combined for a ligation for 16-
18 h at room temperature in a 3:1 insert to vector ratio. At the end of the reaction, 5 μL 
of ligation mixture was transformed in competent E. coli DH5α cells. 
 
2.4.5 Electrocompetent cell preparation 
An overnight culture of 10 mL LB E. coli ET12567/pUZ8002 cells was prepared, with 
added chloramphenicol and kanamycin. 1 mL of the overnight culture was used to 
inoculate 100 mL of LB containing the appropriate antibiotics and incubated at 37°C and 
250 rpm until O.D.600 reached approximately 0.4. After reaching desired OD, the content 
of the flask was split in two falcon tubes and centrifuged at 4°C and 7000 rpm for 5 min. 
The supernatant was discarded, and the pellet was resuspended in 50 mL of sterile, ice-
cold milliQ water. The centrifugation was repeated at 4°C and 7000 rpm for 5 min and 
the supernatant was discarded once more. The contents of both falcon tubes were 
pooled together by resuspending one in 50 mL of sterile, ice-cold milliQ water and then 
transferring it to the other. The wash step was repeated 2 times in total and after the final 
wash step the cells were resuspended in a smaller volume of sterile, ice-cold 10% 
Glycerol (between 1-5 mL depending on cell density), pelleted at 4°C and 7000 rpm for 
5 min. Finally, the pellet was resuspended with no more than 1 mL of sterile, ice-cold 
10% Glycerol to make a very dense cell suspension and was dispensed in 50 µL aliquots. 
These were used either immediately or stored at -80°C for later use. 
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2.4.6 Bacterial transformation 
2.4.6.1 Transformation of chemically competent E. coli 
50 μL cells were mixed with either 5 μL of ligation mix, 2 μL Gibson Assembly mix or 1 
μL of vector DNA and incubated on ice for 30 min. Then cells were heat shocked at 42°C 
for 45 s before returning to ice for a further 2 min. 950 μL of LB medium were then added 
to the transformed cells and recovery was performed at 37°C, 250 rpm for 1 h. Cells 
were finally plated on LB agar with appropriate selection and incubated O/N at 37°C. 
Resulting colonies were screened by colony PCR to identify successful colonies. 
 
2.4.6.2 Transformation of electrocompetent E. coli 
The electroporation cuvettes where prechilled on ice. The electrocompetent E. coli cells 
were thawed on ice, 50 µL per sample and transferred in the cuvette. 5-10 µL of a ligation 
reaction or 1 µL of plasmid DNA were transferred and mixed gently by shaking the 
cuvette. A BIORAD™ pulse controller was set to 25 µF, 1.5 kV, 800 Ω. The samples in 
the cuvettes were electroporated and immediately 950 µL of LB were added and mixed 
by gentle pipetting. The cells in Lb were transferred in 1.5 mL microcentrifuge tubes and 
incubated for 1 h at 220 rpm/ 37°C. After incubation, 10 or 100 µL of the cells were plated 
on LB agar containing an antibiotic. The plates were incubated o/n at 37°C. The following 
day 5 mL of LB with antibiotic were inoculated with a single colony for consequent 
plasmid extraction. 
2.4.7 Plasmid extraction and Sanger sequencing 
The 10 mL of E. coli LB cultures with appropriate antibiotic were established from single 
colonies on plates as described in 2.4.6 or from -80°C 20% glycerol stocks and were 
grown O/N at 37°C, 250 rpm. Plasmid DNA was purified using a QIAprep® Spin Miniprep 
Kit (Qiagen). All constructs generated were sequenced by Sanger sequencing (Eurofins 
Genomics). 
2.4.8 Conjugation in Actinomycetes 
This protocol is based to the conjugation protocol from Kieser et al. (2000) but it has 
modifications to enhance conjugation effectiveness in Saccharopolyspora species. 
Electro-competent cells of E. coli ET12567/pUZ8002 with the oriT containing plasmid 
were transformed and selected for the incoming plasmid only, as described. A colony 
from the plate was inoculated into 5 mL of LB containing chloramphenicol (25 μg/mL 
41 
 
final), kanamycin (50 μg/mL final) and the antibiotic used to select for the oriT-containing 
plasmid and inoculated at 37ºC overnight. A well grown overnight culture was diluted to 
1:100 (500μl) in fresh 50 mL LB and appropriate antibiotics in half concentration than the 
overnight in a 250 mL flask and grown at 37ºC, shaking at 250 rpm until O.D. 600 = 0.4-
0.6 (normally after 4-5 h).  The growth of E. coli cells was stopped by placing the flask 
on ice. The whole broth was transferred in a falcon tube and the cultures were pelleted 
at 2500 rpm at 4ºC. The supernatant was discarded, and the pellet was washed with 50 
mL LB. The wash step was repeated twice and then the E. coli cells were resuspended 
in 1 mL LB. At the same time, 150 μL from the thick spore stock solution (instead of 
commonly used 50 μL) of the strain we aim to conjugate into, were spun to remove 20% 
glycerol, then resuspended in 0.5 mL of LB and heat shocked at 50°C for 10 min. 0.5 mL 
E. coli cells and 0.5 mL spores solution were mixed and plated in various dilutions on 
SF+ M plates containing 10 mM MgCl2. The plates were left to dry in the cabinet and 
then incubated at 28-30ºC for 16-20 h. The 30 mL agar plates were overlayed with 1 mL 
water containing the appropriate amount of antibiotics (nalidixic acid 12.5 g/mL final 
concentration in the plate and antibiotic to select for the incoming plasmid, e.g. 
apramycin 50 μg/mL final concentration). Incubation was continued until exconjugants 
appeared.  
2.4.9 Gibson Assembly 
Reactions were assembled following manufacturer’s instructions containing 10 μL of 
2×Gibson Assembly Master Mix (Gibson et al., 2009), (NEB) and a calculated ratio of 
PCR products, made up with ddH2O to a final reaction volume of 20 μL. Samples were 
then incubated at 50°C for 15 min in a T100™ Thermal Cycler (Bio-Rad), before 
transformation of the ligation mix into NEB® 5-alpha Competent (High Efficiency) E. coli. 
 
2.5 Expression, mutagenesis and complementation 
experiments 
2.5.1 Ordering operons from GenScript®  
The synthetic operons pEVK1, pEVK2 and pEVK3 described in chapters 3 and 4 were 
ordered from GenScript® and received in a pUC57 vector. 
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2.5.2 Disruption of spoAII in Saccharopolyspora sp BR-2231 
In order to disrupt spoAII gene in Saccharopolyspora sp BR-2231, primers eryAf and 
eryAr were designed to amplify 2433 bp of the gene, for cloning as a HindIII-EcoRI 
fragment into the suicide vector pKC1132. This would then be used to disrupt the WT 
chromosomal copy of the gene by single cross-over. A set of sequencing primers were 
used for verification of the construct by sequencing (eryAII_Int1a_forw, 
eryAII_Int1b_forw, eryAII_Int2a_forw, eryAII_Int2b_forw, eryAII_Int3a_rev, 
eryAII_Int3b_rev, eryAII_Int4a_for, eryAII_Int4b_for, eryAII_Int4c_rv). 
  
2.5.3 Construction of a kyaA deletion plasmid 
Two PCR primers, kyaAdelF and kyaAdelR, were used to generate a replacement 
cassette using pIJ10700 as a template. This generated a replacement cassette with a 
hygromycin resistance gene, flanked with FLP recombinase recombination sites. This 
was used to replace kyaA in pEVK3. The kyaAdelF and kyaAdelR primers possess 39 
bp 5’ extensions that correspond to either 39 bp upstream of and including the start 
codon of kyaA in the case of kyaAdelF or 39 bp downstream of and including the stop 
codon of kyaA in the case of kyaAdelR. These 5’ extensions were used by the lambda 
phage recombinase to replace the kyaA gene with the PCR generated hygromycin 
cassette via a double crossover. The product of this process, pWDW55, was then used 
to transform DH5αBT340. This strain has an FLP recombinase gene carried on BT340, 
a plasmid with a temperature sensitive replicon. Transformants were then grown for 16-
18 h in 10 mL of LB at 42°C without any antibiotic selection. Next day a plasmid extraction 
was carried out from those cultures and the plasmids were used to transform DH5α. 
Transformants were then selected for carbenicillin resistance and hygromycin sensitivity. 
This resulted in the plasmid pWDW59 which carries a 81 bp scar in place of kyaA. This 
was confirmed by sequencing using primers deltaKyaAseqF and deltaKyaAseqR.  A 4.6 
kb EcoRI/KpnI fragment of pWDW59 covering the 5’ end of the biosynthetic cluster was 
cloned into the 8 kb vector fragment of EcoRI/KpnI cut pWDW63 to reconstitute the BGC 
but with kyaA replaced with a scar, called pWDW65.  
2.5.4 Complementation of ΔkyaA with an ermE* promoter plasmid 
A PCR product was generated using the GenScript® plasmid pEVK3 as template and Q5 
polymerase with the set of primers cinAcompF and cinAcompR that covered the whole 
coding region of the kyaA gene. That was digested by NdeI/XbaI and cloned into 
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pADW11 also cut NdeI/XbaI, under the control of an ermE* promoter. The vector 
pADW11 is based on pOSV556t, a plasmid that integrates at a pSAM2 integration site 
(Sydor and Challis, 2012), carries a thiostrepton resistance gene for selection in S. 
coelicolor and a carbenicillin resistance gene for selection in E. coli.  This resulted in 
plasmid pWDW61. 
2.5.5 Complementation of ΔkyaA with a kyaR1 promoter plasmid 
A NdeI/EcoRI fragment from pWDW61 carrying the kyaA and thiostrepton resistance 
genes was cloned into NdeI/EcoRI cut pADW19. In this plasmid, the kyaA gene is under 
the control of kyaN promoter, which is activated by an ermE*p::kyaR1 gene also located 
on pADW19.  
2.5.6 Complementation of ΔkyaA in cis 
A partial deletion of kyaA in which the core peptide coding region of kyaA was replaced 
with a StuI restriction site, was constructed. A PCR was generated (with primer set 
KY3smNdeI-F and KY3smStuI-R) covering from the EcoRI site to the second base pair 
of the codon for KyaA Val 59. A StuI site was created using the AGG sequence from the 
last base pair of the E58 codon and the first two base pairs from the V59 codon with   
CCT added to give AGGCCT the StuI site. Six random base pairs were inserted between 
the StuI site and a KpnI site located at the end of the PCR fragment. This was cut with 
EcoRI/KpnI and cloned into EcoRI/KpnI cut pBlueScriptIIKS to yield pWDW68. A further 
PCR was generated (with primers set KY3lgStuI-F and KY3lgNdeI-R2) with a StuI site 
at the end of the PCR corresponding to where the core peptide coding region and stop 
codon of kyaA would have been and with the KpnI site located in the kyaX gene. This 
PCR was cut with StuI/KpnI and cloned into StuI/KpnI cut pWDW68, to give pWDW69. 
The EcoRI/KpnI fragment from this PCR was then subcloned into the 8 kb fragment of 
EcoRI/KpnI cut pWDW63, to give pWDW70.  
This construct has a StuI site were the core peptide coding region had been.   
A synthetic double-stranded operon encoding for the kyamicin core peptide was ordered 
and cloned into pWDW70 via GIBSON. The pWDW70 carrying the synthetic kyamicin 
core peptide was named pEVK10. 
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2.6 Bioassays 
All bioindicator strains used in bioassays were grown from a single colony in 10 mL LB 
for 16-18 h at 37°C. 500 μL of the overnight culture was transferred to 10 mL fresh LB 
and grown till O.D.600 = 0.4 - 0.6. 
2.6.1 Overlay bioassays 
For each Saccharopolyspora strain to be tested either 5 μL or a streak from the spore 
stock were applied in the centre of an SF+M plate and left to grow for seven days at 
30°C. 
500 μL of the exponential culture of the bioindicator strain was mixed with 5 mL of soft 
nutrient agar (SNA). The mixture was used to overlay the Saccharopolyspora plate, left 
to air dry and incubated at room temperature overnight. The result was observed the 
following morning, with a zone of clearance around the Saccharopolyspora streak 
indicating the production of an inhibitory compound. 
2.6.2 Disk and agar diffusion assays 
For assays with crude extracts 20 µL of each dilution were applied to sterile disks (6 
mM), which were allowed to dry and transferred to SNA plates infused with bioindicator 
strains as described above. 
In order to determine the minimum inhibitory concentration (MIC) values of lantibiotic 
compounds a stock solution of 1000 µg/mL in sterile water was prepared, along with 
serial dilutions from 256 – 8 µg/mL. As disk assays resulted in small inhibition zones, 
direction application of the compounds to the agar was trialled. 5 µL of the dilutions were 
applied directly to the agar which allowed for better diffusion of the compounds and clear 
inhibition zones. The MIC was defined as the lowest concentration for which a clear zone 
of inhibition was observed.  
 
2.7 Extraction protocols  
Unless stated otherwise, all small-scale extractions described in chapters 5 and 6, were 
done by mixing equal volumes of solvent and sample, followed by vortexing and shaking 
for 20 min. The mixture was subject to centrifugation and resultant supernatant was then 
analysed by HPLC. 
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2.7.1 Extraction from liquid for isolation of kyamicin 
M1152/pWDW63/pEVK6 was grown in 6 L of tryptic soy broth (TSB) at 28°C for seven 
days. The cells were harvested and extracted at with methanol/water (1:1; 500 mL), with 
ultrasonication for 2 h and subsequent shaking for 16 h. After centrifugation, the 
supernatant was filtered and concentrated under vacuum giving 613.4 mg of crude 
material. This was redissolved in a minimum volume of 50% methanol and loaded on to 
reversed phase solid phase extraction (SPE) cartridges. These were then washed with 
water to remove polar compounds and eluted with 50% methanol. The resulting fractions 
were combined, concentrated under vacuum and then further purified by semi-
preparative HPLC to yield pure kyamicin (2.5 mg). 
2.7.2 Extraction from agar plates 
R5 agar plates were inoculated with M1152/pWDW63/pEVK6 and grown at 30°C for 14-
20 days. The plates were frozen at -20°C for 16 h, thawed and chopped, before adding 
an equal volume of methanol and leaving for 1 h. The supernatant was collected, the 
methanol extraction was repeated, and the collective supernatant was dried down and 
processed as above. 
2.7.3 Extraction from overlay bioassay plates 
All overlay bioassay plates were analysed in the same way. Agar plugs of ¼ inch 
diameter, were cut with a cork borer from the zone of clearing (or close to the growth 
streak in the case of negative control) and transferred to microcentrifuge tubes. Samples 
were frozen at -80°C for 10 min and allowed to thaw. 300 μL of 5% formic acid was 
added to each tube, which was vortexed and shaken for 20 min. The same was subject 
to centrifugation at 13000 rpm for 15 min. The supernatants were carefully collected and 
transferred to filter vials (HSTL labs) for HPLC analysis. 
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2.8 Chemical analysis, isolation and characterisation of natural 
products 
2.8.1 Analytical LCMS 
2.8.1.1 UHPLC-MS 
Measurements were performed on a Nexera X2 liquid chromatograph (LC-30AD) LCMS 
system (Shimadzu) connected to an autosampler (SIL-30AC), a Prominence column 
oven (CTO-20AC) and a Prominence photo diode array detector (SPD-M20A). A 
Kinetex® 1.7 µm C18 100 Å, 100×2.1 mm column (Phenomenex) was used with a 
gradient of water (0.1% formic acid)/methanol. Starting conditions: 90/10, hold at 90/10 
for 1 min, to 0/100 within 9.00 min, hold for 2.00 min, to 90/10 from within 0.5 min, hold 
at 90/10 for 0.5 min. The UHPLC-System was connected to a LCMS-IT-TOF Liquid 
Chromatograph mass spectrometer (Shimadzu). 
2.8.1.2 UHPLC-HRMS 
Data were acquired with an Acquity UHPLC system (Waters Corporation) equipped with 
an ACQUITY UHPLC® HSS T3 1.8 µm, 2.1 × 100 mm column (Waters Corporation) 
connected to a Synapt G2-Si high-resolution mass spectrometer (Waters Corporation).  
For analytical UHPLC a gradient between mobile phase A (H2O with 0.1 % formic acid) 
and mobile phase B (acetonitrile with 0.1% formic acid) at a flow rate of 200 µL/min was 
used. Initial conditions were 1% B for 1 min, ramped to 60% B within 9 min, ramped to 
99% B within 1 min, held for 2 min, returned to 1 % B within 0.1 min and held for 4.9 min.  
MS spectra were acquired with a scan time of 1 s in the range of m/z = 50 - 1200 in 
positive MSE resolution mode. The following parameters were used: capillary voltage of 
3 kV, sampling Cone 40, source offset: 80, source temperature of 120°C, desolvation 
temperature of 350°C, desolvation gas flow of 800 L/h.   
A solution of sodium formate was used for calibration. A solution of leucine encephalin 
(H2O/MeOH/formic acid: 49.95/49.95/0.1) was used as lock mass and has been injected 
every 20 s during the runs. The lock mass has been acquired with a scan time of 0.3 s 
and 3 scans to average. The lock mass (556.2766) has been applied during data 
acquisition. 
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2.8.2 Semi-preparative HPLC 
For purification of EV60 semi-preparative HPLC was performed on a 1100 Series System 
(Agilent Technologies) equipped with a Synergi™ 4 µm Fusion-RP 80 Å LC column 
250×4.6 mm (Phenomenex). The following gradient was used: water (0.1% formic 
acid)/ACN, starting conditions: 90/10, hold for 1 min, to 68/32 within 12 min, to 0/100 
within 0.5 min, hold for 3.5 min, to 90/10 within 0.5 min, hold for 1.5 min. For recovery of 
the material, the collected fractions were concentrated under reduced pressure to 
remove acetonitrile, then loaded onto an SPE cartridge, washed with water and finally 
eluted with methanol and the solvent reduced under reduced pressure.  
For kyamicin semi-preparative HPLC was carried out over a Phenomenex Gemini-NX 
reversed-phase column (C18, 110 Å, 150 × 21.2 mm) using a Thermo Scientific Dionex 
UltiMate 3000 HPLC system. A gradient was used with mobile phases of A: H2O (0.1% 
formic acid) and  B: methanol; 0–1 min 10% B, 1–35 min 10-85% B, 35–40 min 85-100% 
B, 40–45 min 100% B, 45-45.1 min 100-10% B, 45.1-50 min 10% B; flowrate 20 mL/min; 
injection volume 1000 µL. Absorbance was monitored at 215 nm and fractions (20 mL) 
were collected and analysed by LCMS. Kyamicin was observed in fractions 22-25 which 
were combined and concentrated to yield the pure compound as an off-white solid (2.5 
mg). 
2.8.3 Reduction of kyamicin 
Kyamicin (1 mg) was dissolved in methanol (0.5 mL) and added to an aqueous solution 
of 20 mg/mL NiCl2 (0.5 mL). The solution was added to a tube containing 5 mg of NaBH4, 
resulting in the generation of hydrogen gas and the formation of a black Ni2B precipitate. 
The tube was immediately sealed, and the mixture was stirred at 55°C. The reaction 
progress was monitored by UHPLC-HRMS as described above, for which a peak at 8.45 
min with an m/z of 899.3556 was observed for kyamicin ([M + 2H]2+ m/z calculated for 
C76H108N20O25S3 = 899.3551). The successive formation of peaks with the following 
masses were observed: m/z = 884.3767 ([M + 2H]2+ m/z calculated for C76H110N20O25S2  
= 884.3768), retention time 8.38 min; m/z = 869.3990 ([M + 2H]2+ m/z calculated for 
C76H112N20O25S  = 869.3987), retention time 8.01 min and 854.4203 ([M + 2H]2+ m/z 
calculated for C76H114N20O25 = 854.4204), retention time 7.91 min corresponding to the 
successive reduction of the three thioether bridges in the molecule. After 5 h only the 
854.42 m/z ion could be observed, indicating that the kyamicin starting material had been 
completely reduced. The precipitate was collected by centrifugation at 13,000 rpm for 10 
min. As the reaction supernatant contained only trace amounts of the desired product, a 
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fresh solution of MeOH/H2O 1:1 (0.5 mL) was added to the precipitate and it was subject 
to ultrasonication for 30 min. Reduced kyamicin was then detected in sufficient quantities 
for the following fragmentation experiments. 
2.8.4 Fragmentation of reduced kyamicin 
For ESI MS2 fragmentation the mass of interest (854.42) was selected using an inclusion 
list and fragmented using data directed analysis (DDA) with the following parameters: 
top3 precursor selection (inclusion list only); MS2 threshold: 50,000; scan time 0.5 s 
without dynamic exclusion. Collision energy (CE) was ramped between 15-20 at low 
mass (50 m/z) and 40-100 at high mass (2000 m/z). Further increase of the CE to 20-
30/60-120 led to complete fragmentation. 
For MALDI-TOF analysis the samples were mixed with α-cyano-4-hydroxycinnamic acid 
as matrix and analysed on an AutoflexTM Speed MALDI-TOF/TOF mass spectrometer 
(Bruker DaltonicsTM GmbH, Coventry, UK). The instrument was controlled by a 
flexControlTM (version 3.4, Bruker) method optimised for peptide detection and 
calibrated using peptide standards (Bruker). For sequence analysis fragments produced 
by PSD were measured using the LIFT method (Bruker). All spectra were processed in 
flexAnalysisTM (3.4, Bruker). 
 
2.8.5 NMR 
NMR measurements were performed on both Bruker AVANCE III 400 MHz and Bruker 
AVANCE III 800 MHz spectrometers. Chemical shifts are reported in parts per million 
(ppm) relative to the solvent residual peaks of DMSO-d6 (1H: 2.50 ppm, quintet; 13C: 
39.52 ppm, septet). 
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3 Discovery and characterisation of kyamicin, a new 
lantibiotic from plant-ant derived Saccharopolyspora 
strains 
3.1 Introduction 
The current need for novel antimicrobial compounds focused our research on the 
investigation of three Saccharopolyspora strains that were isolated from fungus farming 
Tetraponera penzigi ant samples from various locations from Kenya. Previous 
investigation of new Streptomyces species isolated from this underexplored ecological 
niche identified antimicrobial polyketide natural products with activity against multidrug-
resistant microorganisms (Qin et al., 2017). 
The three strains were sequenced using the PacBio RSII platform and bioinformatics 
analysis suggested the presence of approximately 23 BGCs in each case. Many of these 
appear to encode new or unusual members of chemotypes known to possess potent 
biological activity, including several potentially anti-infective molecules. The isolate 
Saccharopolyspora sp. KY21 proved most tractable under laboratory conditions and was 
chosen as the basis for further study.  
We noticed that all three strains contain a cinnamycin-like BGC (Widdick et al., 2003) 
that proved silent despite culturing under a wide range of conditions. Cinnamycin is a 
type B lantibiotic produced by Streptomyces cinnamoneus DSM 40005 and is active 
against a broad range of Gram-positive bacteria (Hans-Georg Sahl and Bierbaum, 1998). 
Therefore, the aim of this work was to activate the cinnamycin-like BGC and 
subsequently isolate and characterise the compound herein referred to as kyamicin (in 
reference to the Kenyan origin). We eventually activated the cinnamycin-like BGCs by 
heterologous expression of two native genes under a constitutive promoter: these were 
a PE methyl transferase resistance gene, and a pathway-specific positive regulator, two 
essential genes for the expression of lantibiotics as described in literature (O’Rourke et 
al., 2017). This yielded the novel antibiotic kyamicin. 
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3.2 Objectives 
The main objectives of this project were to: 
• Investigate the cinnamycin-like BCG present in three novel Saccharopolyspora 
strains.  
• Activate the kyamicin cluster in the native host. 
• Heterologously express of the kyamicin cluster in Streptomyces coelicolor 
M1152. 
• Scale up the production of kyamicin, to isolate material for characterisation of its 
chemical structure and to test its bioactivity. 
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3.3 Genome sequencing of KY strains  
The Saccharopolyspora strains KY3, KY7 and KY21 were isolated from the domatia of 
T. penzigi fungus farming plant ants isolated from two different locations in Kenya. The 
T. penzigi workers were provided by Naomi E. Pierce (Harvard, U.S.A.) and were 
sampled from Kitengela and Ngong Hills from southern Kenya, as well as Mpala Road 
from central Kenya as shown in Figure 3.1 (Seipke et al., 2013). Tetraponera 
microbiomes contain more than 75% Proteobacteria but interestingly only 5% of 
Actinobacteria. 
 
Figure 3.1: Relative pyrotag abundance of phyla in cuticular microbiomes of 
Tetraponera ants. The cuticles of the ants are dominated by Proteobacteria. Used with 
permission from MicrobiologyOpen (Seipke et al., 2013). 
We explored those three fungus-growing, ant-associated strains using a combined 
approach of genomics, unbiased metabolomics, and bioassays. The strains were firstly 
genetically analysed. 
After amplifying 16S rDNA and Sanger sequencing with the universal primers 533F and 
1492R it was shown that KY3 and KY7 were identical, while KY21 had a single base pair 
difference. (Genbank accession numbers JX306001, JX306003, JX306004, 
respectively). All three strains identify with Saccharopolyspora 16S rDNA sequences 
available in public databases by 99%.  
Genomic DNA was then isolated from the KY strains and sequenced at the Earlham 
Institute (Norwich, UK) via PacBio with SMRT sequencing technology and assembled 
using the HGAP3 and HGAP2 pipeline (Chin et al., 2013).  
The genome analysis was performed by Dr Juan Pablo Gomez-Escribano. Assembly of 
the sequence data for strain KY21 gave a contig of 6370354 bp that represents a circular 
chromosome; this also contains a plasmid of 50300 bp. The strain KY3 is organized in a 
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circular chromosome of 6328480 bp. For strain KY7 we obtained two contigs of 4932021 
and 1392929 bp that do not share any overlapping sequence and most likely represent 
a split circular chromosome.  
After performing an alignment between the KY3 and KY7 genome sequences with RAST 
SEED Viewer and BLAST dot plot (Aziz et al., 2008, Boratyn et al., 2012),a full synteny 
was shown along their genomes with 99-100% sequence identity at the nucleotide level 
suggesting that KY3 and KY7 are the same strain and are different to KY21. A visual 
representation of the genome of KY21 is presented in Figure 3.2. 
 
Figure 3.2: Saccharopolyspora KY21 genome as a circular plot. The tracks from the 
outside to the inside represent: Forward CDS; Reverse CDS; rRNA - green and tRNA – 
pink; clusters – red; GC skew [(GC)/(G+C)].  
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After annotating the sequencing data of the strains with antiSMASH (Weber et al., 2015) 
it was observed that the three genomes encode for 23 BGCs that mostly overlap (Table 
3.1).  This project is focused on a cinnamycin-like lantipeptide BGC (highlighted) present 
in all three strains. 
 
Table 3.1: antiSMASH output of strain Saccharopolyspora sp. KY21. List of BGCs with 
prediction of known compounds based on structural patterns. Wherever the similarity 
was lower than 20 %, it has been annotated as no significant similarities. The lantipeptide 
cinnamycin-like BGC has been highlighted. 
antiSMASH 
Cluster No. 
BGC type Position BGCs of compounds 
with highest 
similarity (%) 
from to 
1 Ectoine 956878 967267 Ectoine (75%) 
2 Terpene 1280939 1302951 - 
3 Terpene 1603794 1625917 No significant 
similarities 
4 NRPS 1630963 1692484 No significant 
similarities 
5 T1PKS 2399316 2448369 No significant 
similarities 
6 Aminoglycoside/ 
aminocyclitol 
2798692 2819888 No significant 
similarities 
7 Lassopeptide 2966632 2988078 Chaxapeptin (28%) 
8 Trans-AT PKS 2976109 3056206 Dorrigocin/migrastatin 
(81%) 
9 T2PKS 3090576 3133037 Tetracenomycin 
(33%) 
10 Terpene 3197311 3219704 No significant 
similarities 
11 Terpene 3681982 3703022 Isorenieratene (57%) 
12 NRPS 3741605 3797270 Streptothricin (83%) 
13 Other 4030163 4074212 No significant 
similarities 
14 Terpene 4072067 4098200 Hopene (30%) 
15 NRPS-T1PKS 4331679 4388369 SGR_Polycyclic 
tetramate 
macrolactam (50%) 
16 NRPS 4391798 4456904 Coelibactin (54%) 
17 Arylpolyene 4528923 4570269 No significant 
similarities 
18 Bacteriocin-
Lantipeptide-NRPS 
4693417 4743949 Cinnamycin (47%) 
19 Terpene 4840778 4861980 No significant 
similarities 
20 T1PKS 5022943 5142561 FR-008 (76%) 
21 Terpene 5926466 5949174 Brasilicardin_A (45%) 
22 Butyrolactone 6010332 6022041 - 
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3.4 Annotation of the kyamicin BGC 
As mentioned above, in all three Saccharopolyspora KY strains, we observed the same 
cinnamycin-like BGC. In collaboration with Dr David Widdick, the cluster was studied, 
and annotated. The kyamicin BGC includes all the genes essential for the production of 
the lantibiotic and it resembles the cinnamycin cluster as shown in Figure 3.3.  
 
 
Figure 3.3: Comparison of  A. kyamicin (this study) and the B. cinnamycin (Widdick 
et al., 2003) BGCs. 
 
When we compared the kyamicin BCG to the cinnamycin one, we saw that all the 
biosynthetic and regulatory genes necessary for the production and export of the 
lantibiotic were present in the kyamicin cluster and homologous to the ones for 
cinnamycin. We also noted that although cinorf11 is not essential in the heterologously 
expressed cluster, it is still present in these clusters. Also, in Figure 3.4, I present the 
comparison between the amino acid sequence of the core peptides of kyamicin and the 
other known lantibiotics of this type: cinnamycin (Widdick et al., 2003), cinnamycin B 
(Kodani et al., 2016), duramycin (Huo et al., 2017) and mathermycin (Chen et al., 2017). 
The amino acid identity between proteins encoded by each BGC is presented in Table 
3.2 and it applies to all three KY strains. Both cinnamycin and kyamicin contain 19 amino 
acids but they differ in seven positions. Whereas cinnamycin has a globular structure 
with one lanthionine (Lan) and two methyllanthionine (MeLan) bridges, kyamicin has 
three MeLan bridges, as do the most closely related molecules, mathermycin and 
cinnamycin B (Figure 3.4).  
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Table 3.2: Amino acid identity (%) between proteins encoded by the cinnamycin 
and kyamicin BGCs. 
Kyamicin Cinnamycin Amino Acid 
Identity  
Function 
KyaN (123aa) CinN (119aa) 79/119 (66%) Formation of lysinoalanine 
bridge 
KyaA (78aa) CinA (78aa) 50/79 (63%) Precursor peptide 
KyaM (1065aa) CinM (1088aa) 627/1080 (58%) Formation of lanthionine 
residues 
KyaX (302aa) CinX (325aa) 175/322 (54%) Hydroxylation of aspartate 
15 
KyaT (327aa) CinT (309aa) 202/292 (69%) Export 
KyaH (294aa) CinH (290) 187/291 (64%) Export 
Not Present CinY - Not essential 
Not present CinZ - Not essential 
Not present Cinorf8  - Not essential 
Not present Cinorf9  - Not essential 
KyaR (216aa) CinR (216aa) 160/209 (77%) Regulation 
KyaK (372aa) CinK (354aa) 195/344 (57%) Regulation 
KyaL (226aa) CinL (236aa) 131/220 (60%) Immunity 
Kyaorf11 (295aa) Cinorf11 (396aa) 94/178 (53%) Not essential 
KyaR1 (260aa) CinR1 (261aa) 129/252 (51%) Regulation 
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Figure 3.4:  Amino acid sequence comparison of the core peptides of lantibiotics 
discussed in this thesis. Sequence alignment of the core peptides of cinnamycin, 
duramycin, cinnamycin B, mathermycin and kyamicin, highlighting the positions of 
posttranslational modifications present in the mature molecules. Lanthionine and 
methyllanthionine rings are indicated by thioether linkages, between cysteines and 
dehydrated serines or threonines, respectively. The hydroxylated aspartate residue, 
D15, and the lysinoalanine bridge between K19 and S6 are indicated. 
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Based on the published biosynthesis of cinnamycin (O’Rourke et al., 2017), in Figure 3.5 
the proposed biosynthesis of kyamicin is presented. 
 
 
Figure 3.5: Proposed biosynthesis of kyamicin. The thioether bridges are formed first 
by a dehydration of T4, T11, T18 and S6 by KyaM to form dehydrobutyrine (Dhb) and 
dehydroalanine (Dha) residues, respectively. After thioether cyclization by KyaM, Dhb 
becomes S-linked Abu and Dha becomes S-linked Ala. D15 is hydroxylated by KyaX and 
the lysinoalanine bridge is formed between Dha6 and K19 catalysed by KyaN.  After the 
core peptide is fully modified, the leader peptide is cleaved proteolytically to yield mature 
kyamicin. 
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The postulated biosynthetic pathway predicts the expected molecular formula of 
kyamicin as C76H108N20O25S3. This corresponds to the loss of four H2O molecules in the 
dehydration steps and one addition of O from the hydroxylation of D15. The structure of 
kyamicin after post-translational modifications is shown in Figure 3.6. 
 
Figure 3.6: Structure of kyamicin after the post-translational modifications. 
Methyllanthionine bridges are indicated by blue thioether linkages, between cysteines 
and dehydrated threonines that become S-linked alanine and aminobutyric acid (Abu) 
residues, respectively. The hydroxylated aspartate residue, D15, is indicated in green 
and the lysinoalanine bridge between K19 and S6 are indicated in pink.  
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3.5 Production of the kyamicin BGC by Saccharopolyspora sp. 
KY strains 
3.5.1 Growth trials for kyamicin detection 
As cinnamycin and duramycin are known to inhibit Gram positive bacteria, the indicator 
strain B. subtilis EC1524 (Widdick et al., 2003) was used to perform overlay assays to 
detect the production of kyamicin.  
None of the KY strains had activity against B. subtilis in preliminary tests, contrary to 
what would be expected for the production of kyamicin. These tests were based on 
growing the strain in a variety of production media (Chapter 2.3.1) and performing disk 
diffusion bioassays. These production media are commonly used in industry as 
screening media for the identification of natural products from actinomycetes. They were 
brought to our lab by Prof. Barrie Wilkinson from GlaxoWellcome, and they are described 
as SM media in Chapter 2. The selection of these 13 media, out of a larger group of 
media available, was made based on differences in composition, pH and additives. The 
aim of this selection was to vary as much as possible the potential metabolic profile of 
the strain. 
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3.5.2 Design and construction of synthetic operons for kyamicin activation 
In order to activate the transcription of the kyamicin BGC, we designed and ordered two 
synthetic artificial operons of kyaL, the PE-methyl transferase that provides resistance 
and kyaR1, the Streptomyces antibiotic regulatory protein (SARP). SARPs are confined 
to and have been studied largely in streptomycetes. Their sole role appears to be the 
regulation of antibiotic production (stationary phase onset) (Wietzorrek and Bibb, 1997). 
They act as transcriptional activators and appear to recognise hexameric repeats every 
11 bp. SARPs are also activators of their dependent promoters (Barreales et al., 2018).  
This cloning strategy was based on the reported role of these two genes at the onset of 
cinnamycin biosynthesis (O’Rourke et al., 2017). The two constructs differed in the order 
of the genes (kyaR1-kyaL or kyaL-kyaR1), but both had the same short intergenic region 
carrying a kyaN ribosome binding site (RBS) separating the genes (Figure 3.7). The 
reason why the kyaN ribosome binding site was chosen to be part of the design, is 
because it is an almost perfect RBS. The synthetic constructs were received as pUC57 
based vectors with pUC57/pR1L, named pEVK1 and pUC57/pLR1, named pEVK2. 
 
 
Figure 3.7: Schematic of the two synthetic artificial operons of kyaL, the PE-methyl 
transferase that provides resistance, and kyaR1, the Streptomyces antibiotic 
regulatory protein (SARP)- the homologs of cinR1 and cinL.  
We hypothesised that by sub-cloning these genes into vectors with constitutive 
promoters we could bypass the natural regulation of the SARP, therefore constitutively 
expressing the SARP and the resistance gene.  
Each of the two synthetic operons were cloned into the φBT1-based integrative 
expression vector pGP9 as a NdeI/HindIII fragment under the control of the ActII-
ORF4/PactI activator/promoter system (Kuščer et al., 2007) to express it constitutively in 
all three Saccharopolyspora KY strains. This activator/promoter system is commonly 
used in Saccharopolyspora strains to drive the expression of genes, in a constitutive way 
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(Rowe et al., 1998). The plasmid pGP9/R1L was named pEVK4 and the plasmid 
pGP9/LR1 was named pEVK5. 
The resulting plasmids were used to transform E. coli ET12567/pUZ8002, a dam/dcm-
minus strain used in interspecific conjugations with actinomycetes, and subsequently 
mated into Saccharopolyspora KY strains.  
3.5.3 Activation of kyamicin BGC in Saccharopolyspora KY21   
Only in the strains carrying the constructs described in section 3.5.2, a zone of clearing 
of Bacillus subtilis was observed, regardless of the arrangement of the operon. The wild-
type and the strain carrying the empty pGP9 vector showed no inhibition (Figure 3.8). 
 
Figure 3.8: Activation of kyamicin cluster in Saccharopolyspora KY21. Undersides 
of plates streaked with Saccharopolyspora strains overlaid with B. subtilis EC1524. 
Lantibiotic production is indicated by a zone of inhibition of B. subtilis EC1524 around 
the culture - A: KY21 B:KY21/pGP9 C: KY21/pEVK4 D: KY21/ pEVK5. 
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To confirm the production of kyamicin, agar plugs were taken from the bioassay plates, 
(from the clearing zone of positive plates and close to the streak from negative plates) 
extracted and analysed by UHPLC-MS as described in Chapter 2. According to the 
expected molecular formula of kyamicin, we anticipated a monoisotopic [M + H]+ m/z of 
1797.7029 and an [M + 2H]2+ m/z of 899.3551. We observed a peak of 899.3556 (Δ = 
0.5560 ppm) corresponding to the doubly charged molecule in either order of the genes 
in the activation cassette (Figure 3.9). This peak was not present in the negative controls. 
 
Figure 3.9: Extracted Ion Chromatograms (XIC) of extracts from KY21 kyamicin 
bioassay plates. Agar plugs were taken adjacent to the Saccharopolyspora streak, 
extracted with 5% formic acid and analysed by UHPLC-MS (ESI). A peak corresponding 
to the kyamicin [M + 2H]2+ of 899.36 (m/z observed = 899.3556; m/z calculated = of 
899.3551; Δ = 0.5560 ppm) was detected only in KY21/pEVK4 and KY21/pEVK5. XICs 
are scaled such that 100% = a signal intensity of 20,000,000. 
In order to purify kyamicin for further analysis and characterisation scale-up of 
Saccharopolyspora sp. KY21 cultures, in solid SF+M or in liquid SV2, was attempted but 
the material collected was not sufficient to be isolated for further study. Further details of 
the isolation of kyamicin are reported in section 3.8. 
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3.5.4 Activation of kyamicin BGC in Saccharopolyspora KY3 and KY7   
In order to determine whether the same constructs carrying the activation cassettes, 
described above and shown in Figure 3.7, plasmids pEVK1 and pEVK2 were separately 
mated in the Saccharopolyspora KY3 and KY7 to test if the kyamicin cluster could be 
activated in the other KY strains as well. In the case of KY3, the results of the inhibition 
of B. subtilis were very similar to the results of KY21, with the only difference of a slightly 
smaller inhibition zone. This is possibly due to KY3 exhibiting less growth than KY21 
(Figure 3.10). 
 
 
Figure 3.10: Activation of kyamicin cluster in Saccharopolyspora KY3 - Undersides 
of plates streaked with various Saccharopolyspora KY3 overlaid with B. subtilis EC1524. 
65 
 
Lantibiotic production is indicated by a zone of inhibition of B. subtilis EC1524 around 
the culture- 1: KY3 2: KY3pGP9 3: KY3/pEVK4 4: KY3/pEVK5. 
The KY7 strain also grows poorly on agar plates, compared to KY21. In this case, 
intriguingly, only the strain carrying the synthetic operon with kyaR1 first and kyaL 
second showed inhibition against B.subtilis (Figure 3.11). HPLC-MS analysis was carried 
out in a similar way as above and the presence of kyamicin was confirmed in the 
inhibition zones and not in the negative samples. 
 
Figure 3.11: Activation of kyamicin cluster in Saccharopolyspora KY7. - Undersides 
of plates streaked with various Saccharopolyspora KY7 overlaid with B. subtilis EC1524 
Lantibiotic production is indicated by a zone of inhibition of B. subtilis EC1524 around 
the culture. 1: KY7 2:KY7/pGP9 3: KY7/pEVK4 4: KY7/pEVK5. 
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3.6  Heterologous expression of kyamicin BGC  
Having successfully activated the kyamicin BGC in the Saccharopolyspora KY strains, 
the next objective was to express it in a different host. Streptomyces coelicolor M1152 
was chosen as a widely used superhost for expression of actinomycete genes (Gomez‐
Escribano and Bibb, 2011, Widdick et al., 2018). 
3.6.1 Design and construction of synthetic operons for kyamicin 
expression 
In this part of the study, we collaborated with Dr David Widdick, in the design and 
construction of vectors, hence the naming of some plasmids as pWDW (referring to D. 
Widdick) in contrast to pEVK (referring to E. Vikeli). 
In order to achieve the heterologous expression of the kyamicin BGC in M1152, we 
designed a synthetic operon encoding the genes kyaN to kyaH as an EcoRI/XbaI 
fragment as shown in Figure 3.12. This was purchased from GenScript in a pUC57-
based plasmid and named pEVK3. This contains the whole of the intergenic region 
between kyaR and kyaN so as to include the SARP binding site (SARP BS). As 
mentioned above the SARP BS is a binding motif of five to six base pairs, repeated every 
11 base pairs, which is a characteristic of SARPs (Wietzorrek and Bibb, 1997). A 
comparison of the SARP BSs of kyamicin, cinnamycin and duramycin is presented in 
Chapter 4. Transcription is initiated by the cognate SARP, in this case, kyaR1, from the 
kyaN promoter on the 3’- side of the binding site. It also contains the intergenic region 
downstream of kyaH, in case there is a transcription terminator in that region. The 
synthetic operon was cloned into the φC31, integrative, conjugative vector pSET152 
(Kieser et al., 2000) that confers apramycin resistance, yielding pWDW63. This is 
orthogonal to the activation cassette plasmids pEVK6 (pIJ10257/R1L) and pEVK7 
(pIJ10257/LR1). These were constructed based on the two GenScript synthetic artificial 
operons of kyaL and kyaR1 mentioned in section 3.4.2. They were cloned as NdeI/HindIII 
fragments into  pIJ10257  a φBT1 based integrative, conjugative, expression vector with 
a hygromycin resistance marker ,and an  ermE* promoter (Bibb et al., 1985)  to express 
the constructs constitutively in M1152.  
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Figure 3.12: Schematic of synthetic operon carrying genes kyaN to kyaH as an 
EcoRI/XbaI fragment. These genes were expected to be essential for the biosynthesis 
of kyamicin. 
3.6.2 Expression of kyamicin BGC in Streptomyces coelicolor M1152 
The resulting plasmids described in section 3.6.1 were used to transform E. coli 
ET12567/pUZ8002 individually and subsequently mated one after the other into S. 
coelicolor M1152. Several apramycin/hygromycin resistant ex-conjugants were selected. 
When transferred onto bioassay plates and overlaid with B. subtilis EC1524, a zone of 
clearing was observed only in the strain carrying both the BGC and the activator cassette 
with kyaR1 first and kyaL second, pEVK6 (Figure 3.13).  
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Figure 3.13: Undersides of plates streaked with various Streptomyces 
coelicolor strains overlaid with B. subtilis EC1524. Lantibiotic production is indicated 
by a zone of inhibition of B. subtilis EC1524 around the culture. A: M1152, B: 
M1152/pWDW63, C: M1152/pEVK7, D: M1152/pEVK6, E: M1152/pWDW63/pEVK7, F: 
M1152/pWDW63/pEVK6. 
Agar plugs were taken from the zone of clearing or close to the streak in the absense of 
clearing, extracted and analysed as before by UHPLC-MS(ESI). This showed the 
expected [M + 2H]2+ ion for kyamicin only in the strain carrying both the BGC and the 
activator cassette with kyaR1 first and kyaL second, pEVK6 (m/z observed = 899.3547; 
m/z calculated = of 899.3551; Δ = -0.4448 ppm). Kyamicin was not present in the relevant 
controls (Figure 3.14). 
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Figure 3.14: Extracted Ion Chromatograms (XIC) of extracts from M1152 kyamicin 
bioassay plates. Agar plugs were taken adjacent to the Saccharopolyspora streak, 
extracted with 5% formic acid and analysed by UHPLC-MS (ESI). A peak corresponding 
to the kyamicin [M + 2H]2+ of 899.36 (m/z observed = 899.3547; m/z calculated = of 
899.3551; Δ = -0.4448 ppm) was detected only in M1152/pWDW63/pEVK6 with kyaR1 
first and kyaL second. XICs are scaled such that 100% = a signal intensity of 1,500,000. 
 
3.6.3 Expression of kyamicin BGC in Saccharopolyspora erythraea 
superhost 
To further investigate the possibility of scaling up the production of kyamicin, I also 
cloned both of these vectors (pWDW63 and pEVK6) in an industrially optimised version 
of Saccharopolyspora erythraea, kindly provided by Isomerase Therapeutics 
(Cambridge, UK). 
This strain is missing the erythromycin BGC and it has been modified to carry an artificial 
construct with four phage integration sites that allow simultaneous insertion of four 
orthogonal vectors. It also has high conjugation efficiency and all of the above 
characteristics make it an ideal strain for large scale fermentation of natural products. 
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Based on the previous observations, I only proceeded with the cloning of vector pEVK6 
that has the R1L order. The colonies of the conjugation had either a red or a white 
phenotype, which has been reported previously in the literature for Saccharopolyspora 
strains (Cortés et al., 2002). The conjugation resulted in only 2 colonies, one white and 
one red, so I selected one colony of each phenotype to perform the bioassay. 
As seen previously, only the Saccharopolyspora strain that carried both constructs 
showed inhibition against B. subtilis EC1524 (Figure 3.15). Future work will investigate 
the production of kyamicin from this superhost further.  
 
 
Figure 3.15: Saccharopolyspora erythraea superhost carrying the kyamicin BGC 
in an overlay bioassay against B. subtilis EC1524.  
A. Saccharopolyspora erythraea/pWDW63/pEVK6 red phenotype colony  
B. Saccharopolyspora erythraea/pWDW63/pEVK6 white phenotype colony. 
 
 
3.7 Disruption and complementation of kyamicin BGC 
To verify the role of kyaA in the kyamicin pathway we deleted it and attempted to 
complement it in the heterologous host. This would also enable us to investigate whether 
we can replace kyaA with other structural analogues, which could lead to the production 
of other type B lantibiotics. 
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3.7.1 Disruption of kyamicin BGC and abolishment of production 
lanA genes are the structural genes that encode the precursor peptides of lantibiotics. 
Deletion of these genes abolishes lantibiotic production (Widdick et al., 2003). For that 
reason, deletion of kyaA was performed by the REDIRECT method of Gust et al. (2002).  
3.7.2 Construction of a kyaA deletion plasmid 
Dr David Widdick performed the construction of the deletion plasmids described below. 
In order to achieve the deletion of kyaA, the original pUC57 based construct from 
GenScript, pEVK3, that carries the bla resistance gene was used to transform E. coli 
BW25113/pIJ790. This is a strain that carries pIJ790 a plasmid with the arabinose-
inducible recombinase genes from the lambda phage. Two PCR primers, kyaAdelF and 
kyaAdelR, were used to generate a replacement cassette using pIJ10700 as a template. 
This generated a replacement cassette with a hygromycin resistance gene, flanked with 
FLP recombinase recombination sites. This was used to replace kyaA in pEVK3. The 
kyaAdelF and kyaAdelR primers possess 39 base pair 5’ extensions that correspond to 
either 39 base pairs upstream of and including the start codon of kyaA in the case of 
kyaAdelF or 39 base pairs downstream of and including the stop codon of kyaA in the 
case of kyaAdelR. These 5’ extensions were used by the lambda phage recombinase to 
replace the kyaA gene with the PCR generated hygromycin cassette via a double 
crossover. The product of this process, pWDW55, was then used to transform 
DH5αBT340. This strain has an FLP recombinase gene carried on BT340, a plasmid 
with a temperature sensitive replicon. Transformants were then grown for 16-18 hours in 
10 mL of LB at 42 °C without any antibiotic selection. Next day, a plasmid extraction was 
carried out from those cultures and the plasmids were used to transform DH5α. 
Transformants were then selected for carbenicillin resistance and hygromycin sensitivity. 
This resulted in the plasmid pWDW59 which carries a scar in place of kyaA. This was 
confirmed by sequencing using primers deltaKyaAseqF and deltaKyaAseqR.  A 4.6 kb 
EcoRI/KpnI fragment of pWDW59 covering the 5’ end of the biosynthetic cluster was 
cloned into the 8 kb vector fragment of EcoRI/KpnI cut pWDW63 to reconstitute the BGC 
but with kyaA replaced with a scar, called pWDW65.  
3.7.3 KyaA is essential for the production of kyamicin 
E. coli ET12567/pUZ8002 was transformed with plasmid pWDW65, the kyaA deletion 
construct, and then pWDW65 was mated into S. coelicolor M1152 carrying the activator 
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cassette, pEVK6. The absence of kyamicin production was confirmed by the lack of 
B.subtilis inhibition in bioassays (Figure 3.16). 
 
Figure 3.16: Underside of plate streaked with Streptomyces 
coelicolor M1152/pWDW65/pEVK6 strain overlaid with B. subtilis EC1524. 
Kyamicin production is abolished, as shown by the lack of a zone of inhibition of B. 
subtilis EC1524 around the culture. 
 
3.7.4 Attempts to complement ΔkyaA in trans 
3.7.4.1 Complementation of ΔkyaA with an ermE* promoter plasmid 
To further prove the necessity of kyaA to the production of kyamicin, attempts were made 
to complement the deletion described in section 3.6.2 and 3.6.3.  
A PCR product was generated that covered the whole coding region of the kyaA gene. 
That was digested by NdeI/XbaI and cloned into pADW11 also cut with NdeI/XbaI, under 
the control of an ermE* promoter. The vector pADW11 is a pOSV556t based vector 
(Sydor and Challis, 2012) that has a pSAM2 integrase (Raynal et al., 2002) and carries 
a thiostrepton resistance gene for selection in S. coelicolor and a carbenicillin resistance 
gene for selection in E. coli. This resulted in plasmid pWDW61. 
When this plasmid was introduced into S. coelicolor M1152pWDW65pEVK6, the 
expected inhibition of B. subtilis was not observed. Agar plugs were taken and extracted 
as before and no kyamicin was detected. pWDW61 did not complement the ΔkyaA of 
pWDW65. A reason for absence of kyamicin could be that pWDW65 is not producing 
enough transcript to make enough kyaA for kyamicin to be detected in bioassays or that 
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the ΔkyaA mutation is having a polar effect on the transcription of the remaining 
downstream kya biosynthetic genes. 
3.7.4.2 Reconstitution of ΔkyaA with a kyaR1 promoter plasmid 
Based on the negative results of section 3.7.4.1, we cloned the same PCR fragment 
encoding kyaA used previously, in pADW19, aiming to produce more kyaA transcript and 
complement the ΔkyaA phenotype. pADW19 was built by Dr David Widdick the same 
way as pADW11 with the exception that it has an ermE*p::kyaR1  promoter and a kyaN 
promoter.  In pADW19 then, we introduced an NdeI/EcoRI fragment from pWDW61 
carrying the kyaA and thiostrepton resistance genes, under the control of kyaN promoter, 
which is activated by the mentioned ermE*p::kyaR1 gene. This resulted in plasmid 
pWDW66. 
When this plasmid was introduced into S. coelicolor M1152/pWDW65/pEVK6, again the 
expected inhibition of B. subtilis was not observed. Agar plugs were taken and extracted 
but no kyamicin was detected. For this reason, we changed approach and tried 
complementing a partial ΔkyaA in cis. 
 
3.7.5 Successful reconstitution of partial ΔkyaA in cis 
A diagram of this experiment can be seen in Figure 3.17. 
 
Figure 3.17: Diagram of experimental design for partial complementation of ΔkyaA 
and introduction of other type B lantibiotic core peptides. 
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A partial deletion of kyaA in which the core peptide coding region of kyaA was replaced 
with a StuI restriction site was constructed. A PCR was generated covering from an 
EcoRI site introduced to the first base pair of the codon Val 59 of kyaA. A StuI site was 
created using the AGG sequence from the last two base pairs of the E58 codon and the 
first base pair from the V59 codon and added CCT to give AGGCCT, the StuI site. Six 
random base pairs were inserted between the StuI site and a KpnI site located at the 
end of the PCR fragment. This was cut with EcoRI/KpnI and cloned into EcoRI/KpnI cut 
pBlueScriptIIKS to yield pWDW68. A further PCR was generated with a StuI site at the 
end of the PCR corresponding to where the core peptide coding region and stop codon 
of kyaA would have been and with the KpnI site located in the kyaX gene. This PCR was 
cut with StuI/KpnI and cloned into StuI/KpnI cut pWDW68, to give pWDW69. The 
EcoRI/KpnI fragment from this PCR was then subcloned into the 8 kb fragment of 
EcoRI/KpnI cut pWDW63, to give pWDW70. This construct has a StuI site were the core 
peptide coding region had been. A synthetic double-stranded oligo encoding for the 
kyamicin core peptide was ordered and cloned into pWDW70 via GIBSON (Gibson, 
2010) and mated into M1152/pEVK6 along with empty pWDW70 as negative control. 
The pWDW70 carrying the synthetic kyamicin core peptide was named pEVK10. 
As a result, the strain carrying the activator cassette and the synthetic kyamicin core 
peptide with the remainder of the leader, complemented the mutation of ΔkyaA and the 
production of kyamicin was restored (Figure 3.18 and Figure 3.19). 
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Figure 3.18: Undersides of plates streaked with strains of S. coelicolor M1152 
overlaid with B. subtilis EC1524 after complementing ΔkyaA. A. 
M1152/pEVK6/pWDW70, B.  M1152/pEVK6/pEVK10. Inhibition was observed only for 
the strain carrying the activator cassette and the vector carrying the synthetic kyamicin 
core peptide. 
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Figure 3.19: Extracted ion chromatograms (XICs) of extracts from kyamicin 
complementation bioassay plates. Agar plugs from the plates in Figure 3.18 were 
extracted as described previously and analysed by UHPLC-MS (ESI). A peak 
corresponding to the kyamicin [M + 2H]2+ of 899.36 (m/z observed = 899.3556; m/z 
calculated = of 899.3551; Δ = 0.5560 ppm) was observed only in M1152/pEVK6/pEVK10. 
XICs are scaled such that 100% = a signal intensity of 10,000,000. 
 
 
3.8 Scale-up and isolation of kyamicin 
In order to fully characterise the kyamicin, it was necessary to scale-up the production to 
isolate sufficient quantities of the molecule. As mentioned above, scale-up of 
Saccharopolyspora sp. KY21 cultures, in solid SF+M or in liquid SV2, did not give enough 
material for further study. 
In collaboration with Dr Sibyl Batey, we tested the kyamicin production of S. coelicolor 
M1152/pWDW63/pEVK6 in small volumes of tryptic soy broth (TSB) liquid media, which 
S.coelicolor is known to grow very well in (Gomez‐Escribano and Bibb, 2011). Kyamicin 
was being produced in detectable amounts in small-scale trials, so we proceeded with 
the scale-up growth of the heterologous host strain.  
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3.8.1 Purification of kyamicin 
S. coelicolor M1152/pWDW63/pEVK6, was grown in 12 flasks of size 2500 mL with 500 
mL TSB in each, (giving a total of 6 L) at 28°C for seven days. After that, the cells were 
harvested and extracted with 500 mL of methanol/water in ratio 1:1 by sonicating for two 
hours and shaking for 16 to 18 h. After centrifugation, the cell pellet was discarded, and 
the supernatant was filtered and concentrated. The resulting residue was re-dissolved 
and passed-through a SPE column and eluted with a gradient of water, to remove polar 
compounds such as sugars. The fractions that contained kyamicin were combined and 
concentrated before further purification. The resulting extract was subjected to two 
repetitions of semi-preparative HPLC to yield 2.5 mg of pure kyamicin. 
3.8.2 Chemical characterisation of kyamicin 
The chemical characterisation of kyamicin was performed with the aid of Dr Sibyl Batey. 
3.8.2.1 Reduction and Fragmentation 
Tandem mass spectrometry (MS/MS) is commonly used to characterise peptide natural 
products. In the case of lantibiotics, the lanthionine bridges hamper the fragmentation 
impeding the characterisation of these molecules. In order to circumvent this issue, it has 
been reported (Martin et al., 2004, He et al., 2007) that chemical reduction of the 
lanthionine bridges is possible using NaBH4-NiCl2. A modified version of the published 
protocols was carried out, as described in section 2.8.3. LCMS(ESI) analysis of the 
product showed an [M + 2H]2+ ion at 854.4203 m/z, in agreement with the calculated m/z 
of 854.4204 (Δ = -0.11704) corresponding to the loss of three sulphur atoms and gain of 
six hydrogen atoms, giving the molecular formula C76H114N20O25, Figure 3.20. 
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Figure 3.20: Reduction of kyamicin. A: Chemical structure of kyamicin corresponding 
to a molecular formula of C76H108N20O25S3 (m/z calculated: 899.3551, m/z observed for 
purified kyamicin: 899.3556). B: Chemical structure of kyamicin after reduction of the 
three thioether bonds corresponding to the loss of three sulfur atoms and gain of six 
hydrogen atoms to give a molecular formula of C76H114N20O25; m/z calculated: 854.4204, 
m/z observed: 854.4203 (Δ = -0.11704). Intact and reduced thioether bridges are shown 
in blue; the lysinoalanine bridge is shown in pink, the hydroxylation of D15 is shown in 
green. 
 
To confirm the connectivity of the peptide, the MS/MS analysis was carried out using 
both ESI and matrix-assisted LASER desorption ionization (MALDI) methods. The 
clearest spectrum was achieved with MALDI MS/MS, showing the complete ion series 
for the peptide, Figure 3.21. As had been suggested previously  (Kodani et al., 2016),  
fragmentation of the lysinoalanine bridge occurred via a rearrangement resulting in a 
glycine at residue six and N=C double bond at the end of the K19 side chain. 
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Figure 3.21: Fragmentation of reduced kyamicin. MALDI MS/MS fragmentation 
showed the y ion series of the reduced peptide. The fragmentation of the lysinoalanine 
bridge occurred via a rearrangement resulting in a glycine at residue 6 and N=C in the 
side chain of K19. The expected connectivity for the complete peptide was observed. 
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3.8.2.2 NMR 
Whilst the MS fragmentation results matched the predicted structure, the gold standard 
of small molecule analysis is NMR as it provides information about the structural and 
spatial relationships between different atoms. Therefore, to confirm the purity and 
connectivity of kyamicin, NMR analyses were carried out by Dr. Sibyl Batey. The sample 
was dissolved in deuterated dimethylsulfoxide (DMSO) and a 1H NMR spectrum was 
recorded at 800 MHz, Figure 3.22. Two-dimensional NMR experiments were then carried 
out, including HSQC, TOCSY, and NOESY, which enabled the identification of proton-
carbon correlations. In total, 13 of the 18 anticipated amide protons could be identified. 
These correspond to 13 spin systems in the TOCSY spectrum, which is consistent with 
what is observed for cinnamycin B (Kodani et al., 2016). These spin systems could be 
putatively assigned based on their spatial relationship determined from the NOESY 
spectrum. Coupling in the HSQC spectrum then allowed identification of several C atoms 
in the molecule. All the two-dimensional spectra can be found in Appendix 2. 
 
Figure 3.22: 1H NMR spectrum of kyamicin in d6-DMSO. 
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3.9 Bioactivity of kyamicin 
After isolating pure kyamicin, the activity of the compound against various bioindicator 
strains was compared with the commercially available compounds cinnamycin and 
duramycin. 
3.9.1 Kyamicin inhibits B.subtilis at a Minimum Inhibitory Concentration 
(MIC) of 128 μg/mL 
The application of pure kyamicin in preliminary disk diffusion assays showed weak 
inhibition and so direct application of the compound on the agar was trialled. The zone 
of inhibition was greater, indicating that the compound binds to the disks as described 
for other compounds (Scott, 2017). As shown in Figure 3.23, kyamicin inhibits B. subtilis 
EC1524 at a Minimum Inhibitory Concentration (MIC) of 128 μg/mL, whereas duramycin 
inhibits at 32 μg/mL and cinnamycin at 16 μg/mL.  
 
Figure 3.23: Comparative bioassay of kyamicin, duramycin and cinnamycin 
against B. subtilis EC1524. Direct application of serial dilutions of the compounds in 
water to determine the MIC of each substance. NC = H2O as a negative control. 
 
3.9.2 Kyamicin inhibits a range of Gram-positive bacteria in overlay assays 
S. coelicolor M1152/pWDW63/pEVK6 was tested in overlay bioassays against a variety 
of clinical bacterial strains. Inhibition was only observed against the Gram-positive 
indicator strains as anticipated (Figure 3.24). 
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Figure 3.24: Undersides of plates streaked with M1152pWDW63pEVK6 , overlaid 
with A. Micrococcus luteus, B. B. subtilis ESKAPE, C. B. subtilis 168 wild-type, D. 
Staphylococcus epidermidis ESKAPE, E. Methicillin-resistant S. aureus (MRSA), F. 
Vancomycin-Resistant Enterococcus faecium 6295 (VRE), G. E. coli ATCC 25922. 
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3.9.3 Kyamicin inhibits Streptomyces antibioticus  
Cinnamycin B is closely related lantibiotic to kyamicin with only two different amino acids 
in its core peptide sequence. This compound was reported to exhibit activity against 
Streptomyces antibioticus but not against B.subtilis (Kodani et al., 2016). The activity of 
kyamicin against S. antibioticus TU1798 was therefore investigated. The inhibition zone 
observed was much smaller than the equivalent zone from duramycin and cinnamycin 
(Figure 3.25). This fact raises interesting questions about the diversity of lantibiotic 
activity and how small amino acid variations impact on bioactivity.  
 
Figure 3.25: Comparative bioassay of kyamicin, duramycin and cinnamycin 
against Streptomyces antibioticus TU1798. Direct application on agar of 5 μL of 1 
mg/mL of each compound. NC = H2O as a negative control. 
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3.10  Discussion 
The first objective of this project was to study the cinnamycin-like BGC in the 
Saccharopolyspora strains KY3, KY7 and KY21. Based on the analysis of the genomes, 
it was shown that the three strains are quite similar and the predicted BGCs are 
overlapping, despite having been sampled from two different locations. This also makes 
the existence of the same kyamicin BGC in all three strains very intriguing and serves to 
illustrate the importance of investigating unusual ecological niches in the search for novel 
antibiotics.  Kyamicin is a new addition to the lantibiotics family, a class of antibiotics that 
target phosphatidylethanolamine (PE) in bacterial cell walls. The importance of 
lantibiotics has been emphasized in recent years. For example, duramycin is in phase II 
of clinical trials for the treatment of cystic fibrosis (Oliynyk et al., 2010). 
The second objective was to activate the kyamicin cluster in the native host. This was 
achieved by designing an activation cassette comprised of a SARP and a 
methyltransferase, which functions to provide resistance via the methylation of PE in the 
host membranes. This is the first time that the utilisation of the SARP and the 
methyltransferase has been reported to successfully switch on a silent lantibiotic cluster. 
The order of the genes at the operon did not matter for the activation in KY21.  
When expressing the kyamicin cluster in Streptomyces coelicolor M1152, only the 
construct with the SARP first (pEVK6) was operational. There are many possible reasons 
for this discrepancy between the heterologous host and the native strain. One 
explanation is that the RBS from kyaN that was introduced did not function properly. 
Another observation that supports the theory that the resistance kyaL gene is not being 
expressed, is the fact that the strain producing M1152/pWDW63/pEVK6 doesn’t grow 
particularly well on the bioassay plates. Future work will be done to try to express just 
the SARP on its own to investigate if that alone can activate kyamicin production. A 
different intragenic region could also be tried or the downstream genes of kyaR1 or kyaL 
could be tagged to check their expression by using Western Blotting. 
In terms of the scale up of the production of kyamicin, future work will take advantage of 
the successful expression of kyamicin in the Saccharopolyspora superhost to produce 
large quantities. This will be useful for further bioactivity studies or further 
characterisation of the kyamicin molecule, such as three dimensional structural studies.  
After resolving the chemical structure of kyamicin, the bioactivity of this new lantibiotic 
was compared to the known representatives of the lantibiotic family. The most interesting 
finding was the differences in the activity of kyamicin against Gram-positive bacteria 
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compared to the closest in structure (only two differences) reported lantibiotic, 
cinnamycin B. Since the key residues for PE binding are conserved, the differences 
between the two molecules, are unlikely to affect how they bind PE in the membrane of 
the cell, but they could affect how the lantibiotics disrupt the membrane. This could 
explain the differences between the bioactivity of kyamicin, duramycin and cinnamycin 
as well. Cinnamycin might exhibit the highest activity against Gram-positive bacteria of 
the three because of its better ability to penetrate the cell as it is comprised of more 
hydrophobic amino acids. 
Overall, this work showcases how genome-led chemistry and the activation of silent 
BGCs enables the discovery of new antibiotics. 
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4 Engineering a platform for expression of type B 
lantibiotics 
4.1 Introduction 
A variety of type B lantibiotics have been isolated, and they are most commonly produced 
by Streptomyces spp. and Bacillus spp. (Chatterjee et al., 2005). The rise in readily 
available genomic data has resulted in a plethora of published genomes encoding more 
putative lantibiotic BGCs, suggesting many other type B lantibiotic structures are 
possible. However, there is a discrepancy between this apparent genomic wealth of 
potential lantibiotics and the modest number that have been isolated and characterised. 
The main obstacles to the investigation of these predicted lantibiotics are difficulties 
growing the bacterial species and/or the lack of production under laboratory conditions.  
Given the importance of lantibiotics as potential therapeutic agents with multiple modes 
of action (Shin et al., 2016), the exploration of alternative structures with altered 
bioactivity is highly desirable.  Representatives of this family of antibiotics have made it 
to clinical trials, and include duramycin for cystic fibrosis (Oliynyk et al., 2010) and 
cinnamycin that has been suggested as an alternative treatment for atherosclerosis 
(Hansson, 2005, Marki et al., 1991). 
In Chapter 3, I presented the discovery of a new member of the family of type B 
lantibiotics, kyamicin. This is a circular, 19-membered lantibiotic with activity against 
several Gram-positive bacteria. The process of activating the originally silent kyamicin 
cluster involved two different parts. Firstly, in order to awaken the silent BGC in the 
Saccharopolyspora native host, an activation cassette was engineered that comprised 
of kyaL, the PE-methyl transferase resistance gene, and a pathway-specific positive 
regulator, the SARP kyaR1.  
In parallel, we engineered the machinery for the expression of kyamicin in the 
heterologous host S. coelicolor M1152, using an activator cassette (above) in 
combination with a vector containing the kyamicin biosynthetic genes. That resulted in 
the expression of kyamicin. In the same heterologous host, we deleted kyaA, the 
structural gene of kyamicin with the scope of substituting it with lanA structural 
homologues. This complementation efforts proved especially challenging. For that 
reason, we created a construct with a partial deletion of kyaA in which the core peptide 
coding region of kyaA was replaced with a StuI restriction site. During our efforts to 
complement the knockout of kyaA in this partial construct, we hypothesised that this tool 
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might allow us to construct a platform for the heterologous expression of an array of other 
type B lantibiotics, including those that are new-to-nature.   
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4.2 Objectives 
• Express duramycin and cinnamycin B with kyamicin-based activator cassettes as 
described in chapter 3. 
• Identify type B lantibiotics BGCs in genomic databases based on the similarity of 
the core peptides sequences. 
• Investigate the expression of other potential lantibiotics with kyamicin-based 
activator cassette. 
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4.3 Expression of duramycin BGC in S. coelicolor M1152 
Having used the activator cassette in the heterologous expression of kyamicin in M1152, 
we investigated whether the same kyamicin activator cassette can be used to activate 
the expression of another type B lantibiotic in S. coelicolor M1152. 
Fortuitously, a construct containing the putative duramycin biosynthetic genes had 
previously been constructed and was available to us (Dr. David Widdick, unpublished 
data). This contained the genes durN to durZ that had been identified in Streptomyces 
cinnamoneus cinnamoneus DSM 40005 and inserted into a pOJKKH vector (pOJ436 
based). However, this lacked the immunity and regulatory genes durL, durR1 and durRK. 
These were unintentionally omitted as the presence of a phage insertion site adjacent to 
durZ (Figure 4.1) meant they were not isolated and identified at the time of the work. The 
absence of the regulatory genes meant that heterologous expression of duramycin in S. 
lividans was not achieved, and this construct was not used further. The cloning of the 
duramycin cluster is partially described in Widdick et al, 2003. 
More recently, a paper was published describing the organisation of the duramycin 
cluster in Streptomyces cinnamoneus ATCC 12686 (also known as DSM40005) (Huo et 
al., 2017). We compared the sequence of the duramycin BGC in their duramycin 
producing strain to the one described above and found a homology of 99% between the 
two, as well as the same phage insertion site corresponding to a drop in GC content and 
the presence of a recombinase/integrase adjacent to durZ. Again, the duramycin 
regulatory/immunity genes were not included in their duramycin gene cluster, but we 
could identify them in a similar arrangement as seen above, analogous to kyamicin and 
cinnamycin, at a remote location in the genome (Figure 4.1).  
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Figure 4.1: Schematic of duramycin cluster including biosynthetic and regulatory 
genes. The size of the phase insertion site could not be defined because of the 
organisation of the published genome of Streptomyces cinnamoneus ATCC 12686 in 
two different contigs. 
Based on the above and the fact that the duramycin BCG has a SARP binding site that 
looks almost identical to that of the kyamicin (as well as cinnamycin) as shown in Figure 
4.2, the plasmids pEVK6 (R1L) and pEVK7 (LR1) carrying the activation cassettes, as 
described in chapter 3.6.1, were used to transform E. coli ET12567/pUZ8002 and mated 
sequentially into S. coelicolor M1152 (Gomez‐Escribano and Bibb, 2011) along with the 
pOJKHH vector that carries the biosynthetic genes for the production of duramycin.  
 
Figure 4.2: Sequence alignment of putative SARP binding sites of kyamicin, 
cinnamycin and duramycin amino acid sequences. The alignment was performed 
with ClustalX2. 
 
We observed inhibition of B. subtilis EC1524 in overlay bioassays only for the pEVK6 
carrying strain, in contrast to the pEVK7 strain and the relevant controls (Figure 4.3). 
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Figure 4.3: Undersides of plates streaked with S. coelicolor strains overlaid with 
B. subtilis EC1524. Duramycin production is indicated by a zone of inhibition of B. 
subtilis EC1524 around the culture. A: M1152, B: M1152/pOJKHH, C: M1152/pIJ10257, 
D: M1152/pEVK7, E: M1152/pEVK6, F. M1152/pOJKHH/pEVK7, 
G: M1152/pOJKHH/pEVK6. 
 
Agar plugs were taken from the zone of the clearing or from near the streak, extracted 
and analysed as before by UHPLC-MS(ESI). For the strain with both the duramycin 
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biosynthetic genes and the pEVK6 plasmid an ion with m/z [M + 2H]2+ = 1006.9229, 
corresponding to the expected ion for duramycin (Calculated m/z [M + 2H]2+ for 
C89H125N23O25S3 = 1006.9262; Δ = -3.2773 ppm).  Duramycin was not present in the 
any of the relevant controls or with the pEVK7 activator cassette, with the regulation and 
immunity genes in the alternative order (Figure 4.4). 
 
 
 
Figure 4.4: Extracted Ion Chromatograms (XIC) for duramycin bioassay plates.  Agar 
plugs were taken from the bioassay plates in Figure 4.3 as described previously and 
analysed by UHPLC-MS (ESI). A peak corresponding to the duramycin [M + 2H]2+ of 
1006.93 (m/z observed = 1006.9229; m/z calculated = of 1006.9262; Δ = -3.2773 ppm) 
was detected only for M1152/pOJKHH/pEVK6. XICs are scaled such that 100% = a 
signal intensity of 8,000. 
 
4.4 Genome mining to identify cryptic BGCs for type B 
lantibiotics 
Next, we wanted to investigate whether the system used for the expression of the 
duramycin BGC can be used with other lantibiotic type B core peptides. As discussed in 
section 4.1, we have constructed a vector containing one the kya biosynthetic genes but 
with part of the core peptide sequence of kyaA replaced with a StuI site, pWDW70 
(section 3.7.5). We reasoned that we could use this plasmid in strain M1152pEVK6 as a 
platform for the expression of other type B lantibiotics by inserting core peptide 
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sequences into the StuI site. We used public databases to find orphan type B lantibiotic 
BGCs, using as reference cinA and cinN. All the BGCs found were associated with 
genome sequencing projects. 
21 BGCs were identified, mainly in actinomycetes, but also in cyanobacteria. This is an 
interesting observation since lantibiotics are usually produced by Gram-positive bacteria, 
whereas cyanobacteria are classified as Gram-negative. The list includes the three KY 
strains described in this study as well as three unpublished genomes of Actinomadura 
spp., kindly shared with us by collaborators (NAI698, NAI711, NAI716).  
The core peptides from the strains identified were organised in an alignment made using 
Clustal Omega and the output from Clustal Omega was run through Boxshade (Figure 
4.5). 
Figure 4.5: Alignments of core peptides of all the positives hits at the databases 
on the search based on the lanN, the whole precursor peptide & the core peptide. 
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From this alignment we can make many different observations. The Microbispora rosea 
core peptide bears no resemblance to the cinnamycin family core peptides. It has no 
possibility for a lysino-alanine ring or a hydroxy aspartate residue and all but one of the 
lanthionine rings cannot be formed. It is also the shortest of the potential core peptides 
at 15aa in length.  
The other clearly atypical lanA is from the cyanobacteria Moorea producens 3L. The 
arrangement of the BGC in this organism is unusual in that there are two lanA genes 
associated with it. The lanA1 core peptide cannot form the inner of the lanthionine 
bridges as there is no serine or threonine, but an aspartate. The core peptide from 
Scytonema millei VB511283, a cyanobacterium, lacks an obvious lanN even though it 
has residues that could form a lysine-alanine ring, although it is the only one to have a 
threonine instead of a serine. Strain Actinomadura sp. NAI716 is one of five with 
additional amino acids after the N-terminal lysine of the core peptide with a post-lysine 
alanine residue.  
The core peptide from Actinomadura macra NBRC 14102 also possesses an extra 
alanine after the N-terminal lysine. The core peptide from Nocardiopsis potens DSM 
45234 possesses a post-lysine proline, the core peptide lanA2 from Moorea producens 
3L has a post-lysine serine residue, and the lanA from Actinomadura oligospora ATCC 
43269 has two post-lysine amino acids, a glycine and a glutamine. Assuming these extra 
amino acids are not sequencing artefacts, it could suggest that they do not interfere with 
the lysino-alanine ring formation. 
After the analysis above we chose two lantibiotic core peptides with which to apply the 
expression system. Firstly, that of Actinomadura atramentaria NBRC 14695, which 
produces the previously characterised lantibiotic cinnamycin B (Kodani et al., 2016). 
Secondly, that of N. potens DSM 45234, which has not previously been characterised 
and is more dissimilar to kyamicin.   
4.5 Expression of cinnamycin B BGC in S. coelicolor  
The recently reported lantibiotic cinnamycin B (Kodani et al., 2016) is produced by A. 
atramentaria NBRC 14695. Cinnamycin B differs from kyamicin only in two amino acid 
residues, yet the reported bioactivity profile is very different. Whilst kyamicin is active 
against a range of Gram-positive bacteria (section 3.9.2), cinnamycin B was reported to 
be active only against S. antibioticus and to have no activity against B. subtilis or other 
standard indicator strains. This was therefore chosen as a target to test the expression 
system described in section 3.7.5. 
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4.5.1 Design and construction of synthetic operon for cinnamycin B 
expression 
A synthetic double-stranded oligo encoding for the cinnamycin B core peptide was 
ordered and cloned into pWDW70 via GIBSON (Gibson, 2010) and was independently 
mated into M1152/pEVK6, along with empty pWDW70 as a negative control. The 
pWDW70 carrying the synthetic cinnamycin B core peptide was named pEVK11. 
The strain carrying the activator cassette and the synthetic cinnamycin B core peptide 
showed inhibition against B.subtilis EC1524 (Figure 4.6). Agar plug extracts confirmed 
the presence of cinnamycin B with an m/z [M + 2H]2+ ion of 920.3760 (calculated for 
C79H114N20O25S3 [M + 2H]2+ m/z = 920.3786; Δ = -2.8249 ppm) (Figure 4.7). 
Interestingly, this result is opposing what was previously reported. In order to verify the 
antibacterial activity of cinnamycin B against Gram-positive bacteria, it is required to 
prepare cultures of the producer strain, extract them and isolate the compound and 
attempt fragmentation analysis to reveal the connectivity of the lantibiotic. 
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Figure 4.6: Underside of plates with streaked strains of S. coelicolor overlaid with 
B. subtilis EC1524. A: M1152/pEVK6/pWDW70, B: M1152/pEVK6/pEVK11. Inhibition 
was observed only at the strain carrying the activator cassette and the vector carrying 
the synthetic cinnamycin B core peptide. 
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Figure 4.7: Extracted Ion Chromatograms (XIC) for Cinnamycin B bioassay plates.  
Agar plugs were taken from the bioassay plates in Figure 4.6 as described previously 
and analysed by UHPLC-MS (ESI). A peak corresponding to the cinnamycin B [M + 2H]2+ 
of 920.38 (m/z observed = 920.3760; m/z calculated = of 920.3786; Δ = -2.8249 ppm) 
was detected only for M1152/pEVK6/ pEVK11. XICs are scaled such that 100% = a 
signal intensity of 2,500,000. 
 
There might be various reasons leading to the discrepancy between the published and 
observed effects of cinnamycin B on B.subtilis. Firstly, different strains of B.subtilis were 
used in the two assays. Specifically, I used strain EC1524 in this work whereas Bacillus 
subtilis subsp subtilis NBRC 13719T was used in the Kodani publication. Secondly, they 
are referring to a spot-on-lawn method of assaying antibiotics, where 5 μg of cinnamycin 
B (0.5μL, 10 mg/mL solution) was spotted on an agar plate of the indicator strain. In my 
assay, the producing strain was streaked in the middle of the plate and left to grow for 
seven days before overlaying soft agar containing the indicator strain. The quantity of 
cinnamycin B produced on the plate cannot be accurately quantified without extraction 
of this plate but it is possible that it is greater than in the publication hence this could 
make a potential low activity more obvious. Lastly, we could not exclude the probability 
of an experimental error.  
In order to identify the source of the discrepancy explained above, a potential experiment 
would involve acquiring the producing strain Actinomadura atramentaria DSM 43919T 
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(=NBRC 14695T). Growing the strain in the specified medium and conditions reported in 
Kodani et al., as well as following the exacts methods for cinnamycin B isolation, would 
lead to a quantity of the pure compound that could be tested further.  
 
4.6 Efforts to express other potential lantibiotics from 
genetically distant families 
From the database search (section 4.4), we identified some more distant strains that are 
carrying the lanA gene encoding for a potential lantibiotic. We selected the core peptide 
from N. potens DSM 45234 because it possesses a post-lysine proline. The thought 
behind this choice was to investigate whether the system could tolerate a longer by one 
amino acids core peptide sequence (Figure 4.5). 
4.6.1  Design and construction of synthetic operon for expression of 
putative lantibiotic from N. potens DSM 45234 
A synthetic double-stranded oligo encoding for the N. potens DSM 45234 putative type 
B lantibiotic was ordered and cloned into pWDW70 via GIBSON assembly (Gibson, 
2010) and mated independently into M1152/pEVK6 along with empty pWDW70 as 
negative control. The pWDW70 carrying the synthetic N. potens lantibiotic core peptide 
was named pEVK12. Two colonies were transferred onto bioassay plates and grown for 
7 days at 30°C. 
 
4.6.2 Attempted bioassay of M1152/pEVK6/pEVK12 against B. subtilis 
EC1524 
No inhibition against B. subtilis was observed after performing overlay bioassays of 
M1152/pEVK6/pEVK12 (Figure 4.8).  Agar plugs were taken from the bioassay plates, 
extracted and analysed by HPLC-MS to test whether traces of the predicted compound 
were present. No m/z ion matching the expected molecular formula of C89H129N25O26S3 
was observed ([M + 2H]2+ calculated as 1030.9424; [M + 3H]3+ calculated as 
687.6307). 
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Figure 4.8: Underside of plate with streaked strain of S. coelicolor M1152/pEVK12 
overlaid with B. subtilis EC1524. The strain showed no inhibition against B. subtilis. 
 
As described above, the thought behind selecting the core peptide from N. potens DSM 
45234 was to investigate the elasticity and tolerance of the expression system. This 
specific core peptide sequence is longer by one amino acid, a proline, after the final 
lysine. The absence of a positive bioassay could either mean that the expression system 
cannot accommodate the extra amino acid or that downstream enzymes modified the 
peptide and did not allow for the production and release of the anticipated lantibiotic. 
Further genetic checks need to be performed to investigate whether the modified plasmid 
was properly conjugated into M1152. Nevertheless, pEVK12 was checked and verified 
by Sanger sequencing before conjugation and it also conferred the appropriate 
resistance to the ex-conjugants.  
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4.7 Discussion 
Using the kyamicin activation cassette, we managed to express the duramycin cluster in 
S. coelicolor M1152 and verified production of the compound with overlay bioassays and 
MS. This demonstrates that the activation cassette can be used with a lantibiotic BGC 
from different species. This suggests that the regulation and immunity mechanisms of 
type B lantibiotics are a general phenomenon, and SARPs and immunity genes are 
interchangeable between the different BGCs. Again, pEVK7 (LR1) did not activate 
expression, which may be due to kyaL not being expressed, as discussed previously.  
We then explored the lantibiotic machinery in a different way with the intention to 
engineer a platform for expression of type B lantibiotics. Firstly, cinnamycin B was 
successfully expressed by using this approach. This demonstrates that the kyamicin 
biosynthetic proteins are promiscuous enough to tolerate the modification of alanine to 
valine at position 13 and serine to threonine at position 17. However, as these changes 
are relatively small, further investigation is required to determine the limits of the changes 
tolerated in the core peptide. The next candidates to try are the mathermycins and 
cinnamycin itself.    
The next steps for developing the lantibiotic expression platform further are to explore 
different heterologous hosts, such as the Saccharopolyspora superhost. Other 
possibilities are trying different biosynthetic machinery or activator cassettes, to find the 
most promiscuous biosynthetic proteins and the most widely applicable regulation and 
immunity genes.  
The expression of the putative lantibiotic of N.potens DSM 45234 was not successful. 
The major difference between this core peptide and kyamicin is an extra amino acid in 
the former. It may be that changes in peptide length are less tolerated than amino acid 
substitutions. However, as this lantibiotic is only predicted from genomic data, we cannot 
rule out that it does not encode a functional lantibiotic in the original strain.  
We also showed that cinnamycin B is active against B. subtilis EC1524, contrary to 
previously published data. In this work a different strain, of B. subtilis was used, namely 
B. subtilis subsp subtilis NBRC 13719T, which could account for the different results 
observed. However, as cinnamycin B and kyamicin are so similar it seems unlikely that 
they would have markedly different bioactivity profile.   
Future work on this project will consist of various approaches to establish a robust 
expression system based on the kyamicin machinery. Firstly, we will focus to more 
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similar genera to cinnamycin/kyamicin. Then, the database search will be repeated in 
more depth in order to identify new additions to putative lantibiotic BGCs and attempt to 
express them, regardless of the genera.  
Finally, attempts will be done to introduce variations in the established lantibiotics core 
peptides in order to create randomised analogues of type B lantibiotics that do not exist 
in nature. 
Overall, we demonstrated that firstly the activator cassette described in this work can be 
used for interspecies expression of BGC’s and secondly that we can engineer a platform 
for the expression of orphan type B lantibiotic BGCs. These novel expression systems 
have a lot of potential in the search for novel antibiotics and enable us to gain invaluable 
insight into the structure-function relationship of lantibiotics.  
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5 Discovery of a novel siderophore and antifungal 
compound by untargeted metabolomics and 
bioassay-guided approaches 
 
5.1 Introduction 
The practise of combining genomics with untargeted data-dependent tandem MS is an 
effective way of identifying antimicrobial compounds (Senges et al., 2018). Basically, it 
consists of growing the strain in question in an array of different media with varying 
composition, and the analysis of the culture extracts using UHPLC coupled with MS or 
tandem MS (MS2) (Baltz, 2017). The data are analysed either with specialised software 
and metabolic networks can be constructed to provide a deeper understanding of the 
chemical diversity and structural relationships within the detected metabolomes (Chavali 
et al., 2012, Nothias et al., 2018). The appearance of each compound can be correlated 
with the presence of biological activities in the samples. 
One of the most traditional approaches to identify promising molecules for antimicrobial 
use is the bioassay-guided discovery and purification, combined with chemical structure 
elucidation (Choudhary et al., 2017).  Although this approach harbours the risk of the re-
discovery of known compounds, it is the fastest way to identify antibacterial and 
antifungal molecules, by using indicator strains commonly available in the laboratory 
(Silver, 2011). A previous knowledge about the biosynthetic potential of the strain based 
on genomic information it is extremely useful to reduce the likelihood of rediscovery 
events. 
Overall, this tripartite approach of genomics, metabolomics and bioassays allows us to 
pin down novel antimicrobials and to explore the potential of talented strains from rare 
environmental sources, such as the KY strains. 
Saccharopolyspora sp. KY21 is one of the KY strains isolated from fungus farming T. 
penzigi ants as presented in Chapter 3. This strain was the most tractable under 
laboratory conditions and was chosen as the basis for further studies. Previously I 
outlined how the activation of a silent gene cluster enabled the discovery of a new 
lantibiotic from this strain.  Here I describe how this strain was further probed for novel 
natural products using a combination of untargeted metabolomics and bioassay guided 
approaches.  
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5.2 Objectives 
• Growth of Saccharopolyspora KY21 in multiple media and generation of crude 
extracts. 
• Identification of novel compounds by untargeted metabolomics. 
• Bioassay-guided identification of antimicrobial compounds. 
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5.3 Growth trials and analysis of crude extracts  
In order to investigate which metabolites Saccharopolyspora KY21 can produce, the 
strain was grown in 13 different liquid media (SM media described in section 2.3.2) for 
seven days. These production media are commonly used in industry as screening media 
for the identification of natural products from actinomycetes. The selection of these 13 
media, out of a larger group of media available, was made based on differences in 
composition, pH and additives. The aim of this selection was to vary as much as possible 
the potential metabolic profile of the strain. Spores of the strain KY21 were used to 
inoculate centrifuge tubes containing 10 mL of each medium in duplicate. Samples were 
taken at various timepoints over a period of seven days of incubation and extracted with 
both methanol and ethyl acetate. The crude extracts were both tested for antimicrobial 
activity and analysed by UHPLC-MS. 
5.4 Discovery of the novel NRPS-derived siderophore EV60 
The collective LC-MS data were analysed by Profiling Solutions (Shimadzu Corporation, 
Japan). This is a molecule discovery analysis software for data produced by LCMS 
systems, commonly used for untargeted compound analysis. The software provides the 
ability to combine data from multiple LCMS files and to generate comparative abundance 
profiling studies. Specifically, it processes multiple data files to perform peak picking and 
listing of the m/z values, retention times, and signal intensities for each peak. The output 
of this analysis is a collective table that allows for comparison and overview of the data. 
The signal intensities are displayed with colour-coding and that allows for rapid 
identification of peaks that appear in one medium and not at the rest of the media.  
Based on this, it became apparent that a compound of m/z = 428.1663 with predicted 
formula C18H25N3O9 for the [M + H]+ adduct, was present in the crude extracts deriving 
from only medium SM7 and not in any of the others tested. Analysis of the crude extract 
from SM7 showed that this m/z corresponded to a peak at a retention time of 5.3 min in 
the LC (Figure 5.1). Searching for this specific m/z in Reaxys, a database that provides 
access to experimentally measured data, didn’t give any matches, suggesting it was 
novel. The compound was named EV60 and investigated further. 
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Figure 5.1: Base peak chromatogram of crude ethyl acetate extract of culture of 
KY21 in SM7 (shown in black line).The XIC of EV60 (red line) shows a peak 
corresponding to the m/z of 428.16. 
 
5.4.1 Isolation of EV60 
In order to investigate the nature of compound EV60, spores of strain KY21 were used 
to inoculate a preculture of SV2 (40 mL) for three days. This preculture was used to 
inoculate SM7 medium (1 L divided in 4 x 500 mL flasks) and the culture was incubated 
at 28°C for six days. The whole culture was extracted with ethyl acetate (2 × 500 mL), 
and the combined organic fractions were concentrated under reduced pressure, loaded 
onto a SPE column, washed with water and eluted with 30%, 50% and 100% methanol. 
EV60 was found in the fraction eluted with 30% methanol and resulted in 3 mg of pure 
compound, requiring no further purification. The collected material was subject to 
chemical characterisation and efforts were made to match it with a predicted BGC.  
5.4.2 EV60 Structural elucidation 
To gain further insight into the EV60 structure, NMR analysis, connectivity of the 
molecule and elucidation of the stereochemistry were carried out by Dr. Daniel Heine. 
The sample was dissolved in deuterated DMSO and 1H and 13C NMR spectra were 
recorded. Two-dimensional NMR spectra were then carried out, including HMBC, HSQC 
and COSY. Details of the NMR data are provided in Appendix 2. 
Based on the MS and NMR data we hypothesised that EV60 is a pseudo-tripeptide 
composed of 2,3-dihydroxybenzoic acid (2,3-DHBA), threonine and N5-hydroxyornithine 
(Figure 5.2). Additionally, the hydroxylated amino group of the N5-hydroxyornithine side 
chain features an N5-acetylation. This structure, consisting of a peptide backbone 
comprising 2,3-DHBA and ornithine, a non-proteogenic amino acid, strongly suggests 
that the compound could be the product of an NRPS assembly line. 
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Figure 5.2: Planar structure of EV60 composed of 2,3-DHBA, threonine and 
ornithine. Observed m/z = 428.1663 for [M + H]+, calculated m/z for C18H25N3O9 [M + 
H]+ = 428.1669 (Δ = -1.4013 ppm). Stereocenters indicated by a red asterisk. 
 
Having determined the atomic connectivity of EV60, we wanted to define the 
stereochemistry of the three stereocenters in the molecule. The stereochemistry of the 
threonine residue could be determined by Marfey’s analysis (Marfey, 1984), employing 
acidic hydrolysis of the compound and derivatisation of the hydrolysed peptide using 1-
fluoro-2-4-dinitrophenyl-5-L-alanine amide (FDAA). This analysis was performed by Dr 
Daniel Heine. The retention time of the derivatised hydrolysis product was compared to 
that of the FDAA-derivatives of authentic standards of L- and D-threonine, demonstrating 
the D- configuration of the threonine residue of the backbone peptide (Figure 5.3). Due 
to the lack of a commercial standard for D- or L-N5-hydroxyornithine it was not possible 
to use the same method to determine the stereochemistry at this position. The partial 
stereochemistry of EV60 is shown in Figure 5.4. 
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Figure 5.3: Marfey’s analysis for EV60. Top LC: L-threonine, Second LC: D-threonine, 
Third LC: EV60 hydrolysate, Bottom LC: EV60 hydrolysate + D-threonine co-injected. 
Retention times: L-Thr: 29.6 min, D-Thr: 36.5 min, EV60: 36.5 min. 
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Figure 5.4: EV60 structure showing stereochemistry for part of the molecule. The 
stereochemistry of the threonine residue is the D- configuration. No commercial standard 
was available for D- or L-N5-hydroxyornithine in order to determine the stereochemistry 
at this position. 
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5.4.3 Biosynthetic origins of EV60 
The structure of EV60 suggested that it is a siderophore (Neilands, 1995). Siderophores 
are a structurally diverse group. They can be classified depending on their metal binding 
groups as catecholates (Patzer et al., 2003), hydroxamates (Powell et al., 1980), or 
carboxylates. EV60 features all those characteristic chemical moieties.  Among 
catecholates, 2,3-DHBA is a natural phenol that is incorporated into various 
siderophores, and N5-hydroxyornithine would represent an hydroxamate. In addition, 
EV60 also displays a carboxylic acid derived from the α- carboxylate group of the N5-
hydroxyornithine residue of the molecule.  
In the most parsimonious scenario, the structure of the molecule would suggest that it is 
the product of an NRPS assembly line consisting of three modules with adenylation 
domain specificities for 2,3-DHBA, L- threonine (with no epimerization domain in module 
2) and N5-hydroxy-L-ornithine, respectively.  
As mentioned before, the antiSMASH output of strain KY21 revealed 23 putative BGCs 
and five of them contain NRPS assembly lines, Table 5.1. Interestingly, BGC number 4 
includes a bimodular NRPS with adenylation domain specificities that strongly suggest 
the incorporation of an L- threonine by the N-terminal module of the NRPS, and possibly 
an ornithine by the C-terminal module (as suggested by Stachelhaus code (Marahiel et 
al., 1997), one out of the four prediction tools implemented in antiSMASH). Together with 
the presence of a predicted lysine/ornithine-N-monoxygenase located within the cluster, 
this prediction could mean that in fact this C-terminal module is incorporating N5-
hydroxyornithine in the NRPS product. The presence of a thioesterase domain at the 
end of the bimodular NRPS indicates the end of the NRPS assembly line and the release 
of its product as a carboxylic acid, thus matching the requirements of the elucidated 
structure for EV60. 
However, this BGC 4 lacks an NRPS module with a predicted adenylation domain 
specificity for 2,3-DHBA. There is a standalone adenylation domain (Abe et al., 2017) 
with predicted specificity for small non-polar amino acids (for example gly, ala, val, leu) 
that is unlikely to justify the incorporation of 2,3-DHBA into the NRPS assembly line. 
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Table 5.1: Putative BGCs in KY21 that contain NRPS assembly lines. Note that 
BGC18 is the BGC that encodes for kyamicin, as described in chapter 3. 
antiSMASH 
Cluster No. 
BGC type Position BGCs of 
compounds 
with highest 
similarity (%) 
from to 
4 NRPS 1630963 1692484 No significant 
similarities 
12 NRPS 3741605 3797270 Streptothricin (83%) 
15 NRPS-
T1PKS 
4331679 4388369 SGR_Polycyclic 
tetramate 
macrolactam (50%) 
16 NRPS 4391798 4456904 Coelibactin (54%) 
18 Bacteriocin-
Lantipeptide-
NRPS 
4693417 4743949 Cinnamycin (47%) 
 
Intriguingly, another NRPS-containing BGC (cluster 16) does include a standalone 
adenylation domain showing the expected substrate specificity for 2,3-DHBA. The same 
cluster contains an isochorismate synthase (required for the biosynthesis of 2,3-DHBA), 
thus supporting the specifity of this adenylation domain. In addition to this, high-identity 
homologues of the two additional proteins required for the biosynthesis of 2,3-DHBA 
(isochorismatase and 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase) have been 
found close to each other elsewhere in the KY21 genome. It has been previously 
reported that in some cases the biosynthesis of siderophores requires the cross-talk 
between two or more BGCs spread across a genome (Lazos et al., 2010, Bosello et al., 
2011). Therefore, it could be possible that EV60 is the product of cross-talk between 
BGC4 and BGC16. 
The absence of epimerization domain in the threonine module of BGC4 is surprising, 
given the D-configuration of the threonine residue. Additionally, the threonine-specific 
module of the BGC4 bimodular NRPS does not feature the conserved amino acid motif 
characteristic of dual condensation-epimerization domains (Rausch et al., 2007), which 
could have been a different explanation for the D configuration of the threonine residue 
in the final product. A non-canonical NRPS biochemistry or the action of a hypothetical 
NRP tailoring epimerase could explain our observations, but additional experimental 
evidence and detailed bioinformatics analysis would be required to test these 
hypotheses. Mutational experiments will be performed to test whether the biosynthesis 
of EV60 is a result of cross-talk between multiple BGCs.  
  
113 
 
5.5 Bioassay-guided discovery of an antifungal 
The antiSMASH output of strain KY21 suggested some BGCs encoding possible 
antifungal activity. As shown in Table 5.2, there are two characteristic predictions that 
could encode for an antifungal; a BGC matching a FR-008/Candicidin BGC (Chen et al., 
2003) as well as a SGR_PTM, a polycyclic tetramate macrolactam compound firstly 
isolated and described from Streptomyces griseus (Luo et al., 2013). In order to 
investigate whether strain KY21 could produce an antifungal compound, we employed 
the bioassay-guided approach. 
 
Table 5.2: Putative BGCs in KY21 that could lead to an antifungal compound 
antiSMASH 
Cluster No. 
BGC type Position BGCs of compounds with 
highest similarity (%) from to 
5 T1PKS 2399316 2448369 No significant similarities 
7 Lassopeptide 2966632 2988078 Chaxapeptin (28%) 
15 NRPS-
T1PKS 
4331679 4388369 SGR_Polycyclic tetramate 
macrolactam (50%) 
20 T1PKS 5022943 5142561 FR-008 (76%) 
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5.5.1 Bioassay results with KY21 on agar plates 
KY21 cultures were therefore assayed for anti-fungal activity using the bioindicator strain 
Candida albicans CA-6, kindly provided by Matthew Hutchings lab, UEA (Marconi et al., 
1976). SFM plates were firstly inoculated with strain KY21 spores in the centre of the 
plate and left to grow for seven days at 30 °C. These plates were subsequently overlaid 
with cultures of C. albicans CA-6 mixed with SNA and left at room temperature for 18 h. 
A zone of clearing was observed around the KY21 culture, demonstrating that strain 
KY21 has antifungal activity (Figure 5.5). 
 
 
 
Figure 5.5: Strain KY21 overlay bioassay against C. albicans CA-6. Clearing can be 
noticed around the growth of spores of strain KY21 on an SF+M plate, after 7 days of 
growth. 
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In order to recapitulate the overlay bioassay result, strain KY21 was cultured in the 
selection of the 13 liquid media as described in section 5.3. The crude KY21 methanolic 
and ethyl acetate extracts were then tested using disk diffusion assays to identify the 
antifungal compound. Out of the 13 production media, antifungal activity was observed 
only from the crude methanolic extracts and the water phase of the ethyl acetate 
extractions of media SM12 and SM18. The solvent phase of the ethyl-acetate extractions 
had no activity (Figure 5.6). SM12 was chosen for further study as it is an easier medium 
to handle for extractions. 
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Figure 5.6: Disk diffusion bioassay testing crude methanolic and ethyl acetate 
extracts of strain KY21 against C. albicans CA-6. For extracts from both SM12 and 
SM18 a zone of clearing is observed at the methanolic extracts and the aqueous phase 
of the ethyl acetate extracts. On the top of each plate negative and positive controls have 
been included respective to the solvent tested. A: methanol and B: ethyl acetate as 
negative controls and C: nystatin as positive control 
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Preliminary metabolomics analysis was carried out, but the metabolic profiles of the 
crude extracts were too complicated to be able to assign a peak present to all positive 
bioassay samples. For that reason, the scale up of strain KY21 in SM12 was carried out 
for the isolation of antifungal compound production. A 2 L culture of strain KY21 in 
medium SM12 was grown for seven days and the cells were harvested by centrifugation. 
The supernatant was extracted with ethyl acetate to give an organic and aqueous phase, 
and the cell pellet was extracted with methanol. All the extracts were processed and 
tested in bioassays against C. albicans CA-6 (Figure 5.7). 
In contrast to the smaller scale extractions described earlier, the crude ethyl acetate 
extract showed antifungal activity this time and with a larger inhibition zone than before. 
Preliminary efforts were carried out in order to fractionate the crude extract and to identify 
the active fraction (Figure 5.7).  
Further efforts to fractionate and identify the antifungal were paused by inconsistent 
bioactivity of the extracts, low yields of crude material and isoflavone contaminants from 
the soy-based media. Investigation of this antifungal compound will be continued in 
future experiments. 
Specifically, the next steps of this project will be repeating scale-up of the culture and 
attempting isolation of the bioactive fraction of the crude extract. After acquiring the 
fraction in question, a detailed LCMS analysis can reveal a compound with a specific 
mass and a UV-vis absorption spectrum. It is known from literature that the published 
antifungals presented as possible matches of KY21 BGCs in table 5.2, have 
characteristic UV-vis absorption spectra. Specifically, the FR-008/Candicidin BGC (Chen 
et al., 2003) presents three distinct peaks in the range of 350-420 nm, standard 
absorption pattern of polyenes (Szwarc et al., 2015). Similarly, based on the prediction 
of SGR_PTM, a polycyclic tetramate macrolactam firstly isolated and described from 
Streptomyces griseus (Luo et al., 2013), we can search for UV maxima around 220 and 
323 nm, characteristic for polycyclic tetramate macrolactams (Blodgett et al., 2010). 
Further whole genome bioinformatics analysis is also necessary in order to study further 
possible BGCs and their architecture and ascertain whether they could lead to a natural 
product. The existing computational tools for BGC identification, such as antiSMASH 
(Kautsar et al., 2017, Weber et al., 2015) aim primarily to the identification of known types 
of BGCs and are being constantly updated. Without doubt, this has been important in 
natural product discovery so far but they lack the ability to predict novel types of BGCs 
(van der Lee and Medema, 2016). 
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Figure 5.7: EtOAc extracts of KY21 from 2L liquid culture in SM12 against C. 
albicans CA-6. A and B are two different fractions of C, that have no activity against C. 
albicans whereas C is the crude ethyl acetate extract collected. D: EtOAc_12 is a sample 
from the extraction line of falcon tubes, that hadn’t given any inhibition, so here is used 
as an additional negative control next to E: Ethyl Acetate as negative control since all 
samples used in this bioassay were redissolved in ethyl acetate. 
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5.6 Discussion 
In this chapter, two different approaches for NP discovery are described. Firstly, 
untargeted metabolomics, where the entire metabolome of the bacterial strains grown 
under a variety of media and culture conditions. This allows for rapid identification of 
NPs, including pathway intermediates that might be dismissed in other analyses 
(Watrous et al., 2012). Via this approach a novel NRPS-derived siderophore was 
identified and its stereochemistry was partially elucidated. Siderophores are molecules 
that strongly bind metal ions for absorption into microbes (Saxena et al., 1986). It was 
not possible to find a putative BGC responsible for all the parts of this pseudo-tripeptide. 
We hypothesise that this compound is the result of the cross talk between two BGCs. 
Characteristic reported examples of this phenomenon are the putative siderophore 
erythrochelin, that its production require crosstalk between two separate NRPS BGCs 
(Lazos et al., 2010) as well as rhodochelin, that requires the coordinated expression of 
three independent gene clusters in Rhodococcus jostii RHA1(Bosello et al., 2011). 
Cross-talk between clusters is a very powerful evolutionary strategy since it offers more 
flexibility and more chemical diversity, meaning that with the same number of building 
blocks, more than one compound can be produced (Wandersman and Delepelaire, 
2004). 
Mutational experiments will be conducted in order to identify the building blocks that lead 
to the compound. Specifically, disruption of the adenylation domains in both BGC4 and 
BGC16 with a single recombination event, will reveal if they are actually responsible for 
the NRPS, hence whether the cross-talk hypothesis is accurate. Preliminary mutational 
manipulations of the strain have been attempted, firstly for the adenylation domain 
outside BGC4, and in BGC16, in order to test the theory of cross-talk between clusters. 
Disruption of the NRPS from BGC16 of strain KY21 with the adenylation specificity for 
2,3-DHBA resulted in the mutant strain not growing in minimal media. Growth of the 
mutants in rich media was possible, suggesting that this siderophore is essential for the 
health of the bacteria (unpublished data).  
In terms of the novel siderophore identified, more analyses can be done in the future 
using siderophore binding assays, such as the chromeazurol S (CAS) assay (Alexander 
and Zuberer, 1991) to monitor iron binding. The mode of action of the molecule can also 
be investigated to connect metal chelation to potential starvation of bacteria. 
In terms of the antifungal compound, further work will be carried out in order to pin down 
its structure. Firstly, the scale-up experiments and extractions will be repeated to 
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establish the most robust way of growth of culture and suitable solvent, to solve the issue 
with inconsistency. Once adequate amount of the compound is isolated, NMR analysis 
will be carried out, so we can primarily assign the NP to a putative BGC from the KY21 
antiSMASH output. In order to facilitate this assignment, we can employ the knowledge 
we have from antifungal-related literature, specifically in terms of expected UV-vis 
absorption spectra. Finally, the possibility that activity guided fractionation may lead to 
the isolation of two or more different antifungal molecules should not be dismissed. When 
performing a step-by-step separation of compounds, we base it on differences in their 
physicochemical properties. When we perform a bioassay-guided fractionation, the aim 
is to assess the biological activity of such compounds. Since this procedure usually 
begins with a crude extract that shows activity in a preliminary bioassay, the likelihood 
of simultaneous isolation of more than one NP is high. A thorough testing of the isolated 
fractions can help to identify whether this is the case with strain KY21 and match the 
compounds to the corresponding predicted BGCs.   
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6 Investigation of the biosynthesis of sporeamicin A 
6.1 Introduction 
Sporeamicin is a 14-membered macrolide antibiotic, structurally related to erythromycin 
(Figure 6.1). Sporeamicin A is produced by Saccharopolyspora sp. L53-18 (FERM BP-
2231) (Yaginuma et al., 1992). This strain is a Gram-positive, fast-growing actinomycete 
that sporulates easily in liquid and solid media. It was first isolated from a soil sample at 
Setouchi-cho, Kagoshima Prefecture, Japan (Yaginuma et al., 1992).  
Based on literature data, the molecular formula of sporeamicin A is C37H63NO12 and it 
exhibits a strong UV absorption peak at 276 nm. The aglycone of sporeamicin A is highly 
similar to that of erythromycin A, but with an ether bridge between C12 and C9, a double 
bond between C10 and C9 and a keto group instead of a hydroxyl group at C11. 
Although sporeamicin A has two-fold less bioactivity than erythromycin A against Gram-
positive bacteria, it is more acid stable than erythromycin A, which leads to its higher oral 
bioavailability and better in vivo efficacy in bacterial infections. It is active in vitro against 
Gram-positive bacteria & macrolide resistant strains such as S. aureus (Morishita et al., 
1992). Interestingly, sporeamicin A was first chemically synthesized from erythromycin 
A, only and later was it isolated from Saccharopolyspora sp. L53-18 (Freiberg, 1989).  Its 
structure suggests biosynthetic enzymes with different substrate tolerance compared to 
the erythromycin pathway, or a novel pathway. Intriguingly, the original report on the 
production of sporeamicin A suggests it is the major product of Saccharopolyspora sp. 
L53-18 and makes no comment on the co-production of erythromycin A or its congeners 
(Yaginuma 1992). 
  
Figure 6.1: Comparison of the chemical structures of Sporeamicin and 
Erythromycin variants. Key differences are highlighted in red (Omura, 2002). 
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The structural differences between sporeamicin A and erythromycin A, and the 
mechanisms behind the production of sporeamicin A, might reveal enzymes valuable for 
the bioengineering of new erythromycin analogues. 
Taking inspiration from the semi-synthesis of sporeamicin A from erythromycin A 
described above (Freiberg, 1989, Faghih et al., 1996), we reasoned that a key 
intermediate in the biosynthesis would require at some point a C11-keto group. This 
would increase the ability for dehydration of the hemiketal intermediate formed after 
attack of the C12-hydroxy group on the C9-keto group. 
Our first biosynthetic idea was that a C11-keto group could be formed by action of a 
modified erythromycin-like polyketide synthase. Formation of the dihydrofuran moiety 
could then occur after post-PKS modification to introduce a C12-hydroxyl group (Figure 
6.2). Given the natural order of events that take place during the biosynthesis of 
erythromycin A, and the high substrate specificity, this would imply the equivalent genes 
for making sporeamicin A would behave differently meaning they would be useful for 
bioengineering. 
 
Figure 6.2: Proposed scheme for biosynthesis of sporeamicin A based on the 
known biosynthesis of erythromycin A. Biosynthetic genes are described in Chapter 
1. 
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Our second hypothesis was that erythromycin A is the original product of the pathway 
and sporeamicin A is generated after oxidation of the C11-hydroxyl group to a keto-group 
by oxidative enzymes such as a short-chain dehydrogenase/reductase (SDR)-like or a 
cytochrome P450 monooxygenase (Figure 6.3). 
 
Figure 6.3: Proposed scheme of post-PKS based synthesis of sporeamicin A. 
Erythromycin A is oxidised by either SDR-like or cytochrome P450 enzymes, with 
subsequent ring formation and dehydration to form sporeamicin A. 
Either of these pathways would be interesting and to distinguish between our two 
hypotheses we firstly needed to establish the production of sporeamicin A in the lab. 
Then we aimed to use a genomics-led approach to identify the basis for the differences 
between the two compounds by sequencing Saccharopolyspora sp. L53-18 and 
identifying the BGC.  
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6.2 Objectives 
• Analyse the production of sporeamicin A by Saccharopolyspora sp. L53-18 
(FERM BP-2231).   
• Sequence the genome of Saccharopolyspora sp. L53-18 and identify the 
sporeamicin A BGC. 
• Compare the sporeamicin A and erythromycin A BGCs to identify the novel 
enzymes that lead to sporeamicin A production. 
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6.3 Characterisation of Saccharopolyspora sp. L53-18 
Saccharopolyspora sp. L53-18 was deposited in the Japanese Culture Collection as 
strain FERM BP-2231 (Yaginuma et al., 1992). Due to its inclusion in granted European 
Patent EP 0379 375 we were able to obtain a sample of the strain after application to the 
European Patent Office. 
Prior to arrival of the strain from Japan we acquired a sample of the strain from Isomerase 
Therapeutics (Cambridge, UK) to speed up our work. Strain L53-18 grows readily on 
SFM solid medium where it produces colonies with white aerial mycelium that later 
develop spores. After several days it produces a diffusible red pigment that is 
characteristic of other Saccharopolyspora strains such as S. erythraea (NRRL2338), the 
wild type producer of erythromycin A. This red pigment has been identified as flaviolin 
(Cortés et al., 2002). Also like S. erythraea, strain L53-18 exhibits a relatively high rate 
of spontaneous pleotropic mutation that leads to mixed populations of grey and red 
colonies (Cortés et al., 2002). 
We next investigated the morphology of strain L53-18 in more detail using scanning 
electron microscopy (SEM). The SEM analysis of the strains was performed by Mrs 
Elaine Barclay. We could then compare this to other Saccharopolyspora strains such as 
S. erythraea or S. spinosa (ATCC 49460T), the producer of the insecticide spinosyn A 
(Kirst, 2010) (Figure 6.4), with images of other Saccharopolyspora strains provided from 
the Digital Atlas of Actinomycetes 2 (Society for Actinomycetes, 2013).  In this way we 
could observe that these three strains share the presence of a characteristic spiny sheath 
covering their spore chains. The spore chains variate in the thickness of the hyphae and 
the length of the spores but all 3 strains share this appearance of thorns. 
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Figure 6.4: Scanning electron microscopy (SEM) images of A: Saccharopolyspora 
sp. L53-18 (producer of sporeamicin A), imaged by Mrs Elaine Barclay (JIC) from 
a sample on R5 agar; B: Saccharopolyspora erythraea ATCC49460T by K. Suzuki; 
C: Saccharopolyspora spinosa ATCC49460T by R.C. Yao & F.P. Mertz. Images B 
and C provided by Society for Actinomycetes (2013), http://atlas.actino.jp/. Through 
these images we observe that the Saccharopolyspora strains have a distinct spiny 
wreath covering their spore chains. The spiny wreath varies in length and width, 
depending on the size of the spore chains. 
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6.4 Growth of strain L53-18 and analysis of sporeamicin A 
production 
Cultures of S. sp. L53-18, were grown in sporeamicin seed medium for three days and 
transferred to sporeamicin production medium (both used in Yaginuma et al., 1992), in 
10 mL duplicates and grown at 30 °C for seven days. The samples were prepared by 
extraction with methanol and analysed by HPLC-MS (Figure 6.5). The total ion 
chromatograph (TIC) produced revealed the presence of two distinct peaks at retention 
times shortly after 6.5 and 7.2 min. The first peak appeared to be erythromycin A (m/z 
calculated for C37H67NO13 [M + H]+ = 734.4685; observed m/z = 734.4717; Δ = 4.3569 
ppm) and was not expected based on the literature report. The second peak 
corresponded to sporeamicin A (calculated m/z for C37H63NO12 [M + H]+ = 714.4419; 
observed m/z = 714.4463; Δ = 6.1587 ppm). 
Surprisingly, sporeamicin A was not the main metabolite being produced by the strain 
with erythromycin A being the major metabolite detected, at an approximate ratio of 2:1 
with respect to sporeamicin A.  
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Figure 6.5 Production of sporeamicin A and erythromycin A by strain L53-18. A: 
Total Ion Chromatogram (TIC) of an extract shows peaks corresponding to sporeamicin 
A (peak 1) and erythromycin A (peak 2). B: Mass spectrum of sporeamicin A with a m/z 
of 714.4463 corresponding to the [M + H]+ adduct. C: Mass spectrum of erythromycin A 
with a m/z of 734.4717 corresponding to the  [M + H]+ adduct. D: DAD signal at 276 nm. 
The inset shows absorbance at 276 nm between 5 and 8 minutes with a peak at 7.2 min 
that corresponds to sporeamicin A (peak 1). The results were reproducible.  
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After arrival of authentic strain L53-18 from the Japan Culture Collection named FERM 
BP-2231, we cultured it in parallel with the L53-18 strain under the same conditions and 
observed the same results. 
As noted above there was no indication of the co-production of erythromycin A in the 
primary reports describing the strain L53-18 and identification of sporeamicin A as a 
fermentation product. This was surprising, and we therefore decided to understand if 
sporeamicin A might also be a product of the erythromycin producer S. erythraea 
NRRL2338. An authentic isolate of this strain was obtained from Isomerase Therapeutics 
and grown alongside strain L53-18 using both sporeamicin A (Yaginuma et al., 1992) 
and erythromycin A (Pacey et al., 1998)  production media and conditions. Under all 
conditions tested S. erythraea NRRL2338 produced only erythromycin A, whereas the 
two isolates of the sporeamicin producer (L53-18 and BP-2231) produced a mixture of 
sporeamicin A and erythromycin A (Figure 6.6). 
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Figure 6.6: Extracted Ion Chromatograms (XIC) of fermentation extracts from A: 
Saccharopolyspora sp. L53-18 (Isomerase isolate); B: S. erythraea NRRL2338 wild 
type and C: FERM BP-2231 (Japanese isolate) containing peaks corresponding to 
sporeamicin A in red (1) and erythromycin A (2) in black. S. erythraea wild type produced 
only erythromycin A, whereas the two sporeamicin producers (L53-18 and BP-2231) 
produced a mixture of sporeamicin A and erythromycin A. 
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This behaviour was observed consistently even after testing different culture volumes, 
sampling time points and crossing over the production media (growing S. erythraea in 
strain L53-18 media and vice versa). We then subjected the two L53-18 isolates to two 
rounds of single colony isolation followed by cultivation and extract analysis. However, 
once again there was no change in the ratio of erythromycin A to sporeamicin A. Since 
strain L53-18 produces erythromycin A as well as sporeamicin A, it suggested that both 
metabolites have the same origin and that sporeamicin A is likely to be a product of post-
PKS modification of erythromycin A, supporting our second hypothesis.  On this basis 
we focused all further work on the authentic isolate of strain L53-18 (FERM BP-2231) 
obtained directly from Japan. 
 
6.5 Sequencing of the Saccharopolyspora sp. L53-18 (FERM 
BP-2231) genome 
High molecular weight genomic DNA of strain L53-18 was extracted as described in 
Chapter 2 (Kieser et al., 2000). This was sent to the Earlham Institute (Norwich, UK) for 
sequencing on the Pacific Biosciences (PacBio) platform using SMRT technology and 
assembled using the HGAP3 and HGAP2 pipelines (Chin et al., 2013).  Both assembly 
algorithms offered comparable results. The assembly generated with HGAP3 was 
selected for further bioinformatic analyses. This yielded two contigs of 8335144 bp and 
of 29864 bp. The larger contig represents the whole circular chromosome of the 
bacterium, whereas the smaller contig does not overlap with the larger contig or contain 
the type of repetitive regions usually associated to misassembled sequences (Gomez-
Escribano et al., 2016) meaning it was unlikely to be a sequencing artefact. A contig 
representing a circular molecule is easily identifiable because one end is directly 
repeated at the other end, indicating an overlapping stretch of sequence. In order to 
obtain a full non-repetitive sequence representing the circular chromosome the direct 
repeat of the ends was removed. 
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6.6 Comparison of Saccharopolyspora sp. L53-18 and S. 
erythraea genome sequences    
6.6.1 Genome comparison 
A comparative analysis was performed between the L53-18 genome sequence and the 
genome sequence of S. erythraea NRRL2338 which was previously deposited under 
accession number NC_009142.1 (Oliynyk et al., 2007). BLASTn analysis showed a high 
level of synteny with NC_009142.1. Strain L53-18 appears to have two inversions from 
approximately 2.5M to 3.4M and from 5.3M to 5.8M bases, as shown in Figure 6.7. These 
inversions reflect the fact that two DNA regions on L53-18 have been inverted in relation 
to NC_009142.1. 16S ribosomal RNA data showed 99% similarity to the erythromycin A 
producer. Strain L53-18 has an average GC percentage of 71.1% which is nearly 
identical to S. erythraea (reported 71.15 GC%). S. erythraea contains the erythromycin 
BGC and strain L53-18 has an erythromycin-like cluster with 91% similarity based on the 
antiSMASH output.  
 
Figure 6.7: BLASTn generated dot plot comparing Saccharopolyspora sp. L53-18 
to S. erythraea NRRL2338. This dot matrix shows regions of similarity based upon the 
BLASTn results comparing the two sequences. The query sequence of 
Saccharopolyspora sp. L53-18 is represented on the x-axis, the subject S. erythraea 
NRRL2338 is represented on the y-axis and the numbers represent the bases of the 
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query and the subject respectively. Matching regions are shown in the plot as lines. Plus 
strand matches are slanted from the bottom left to the upper right corner, minus strand 
matches are slanted from the upper left to the lower right. The number of lines shown in 
the plot is the same as the number of matching regions found by BLASTn. 
 
A detailed analysis of the erythromycin-like BGC encoded by strain L53-18 showed that 
it is nearly identical to that published for erythromycin A in S. erythraea NRRL2338 
(Figure 6.8). The same genes are present in both cases and they are organised in the 
same way. The domain and module organisation of the PKS region is conserved 
between the two strains, including the distribution and nature of the -ketoreductase (KR) 
domains within them. Furthermore, the ketoreductase (KR) domains from the 
sporeamicin A cluster are highly similar to their erythromycin A counterparts, with the 
active site residues all conserved. This similarity extends to  KR3, which in the 
sporeamicin cluster presents the same mutations in the active residues (particularly an 
asparagine to serine substitution) that render KR3 from the erythromycin PKS inactive 
(Starcevic et al., 2007) (Figure 6.9). The acyltransferase (AT) domains of each module 
also possess the same substrate specificity, as calculated by MINOWA prediction. For 
example, the active site motifs correspond to selection of  malonyl and 2S-
methylmalonyl-CoA substrates (Minowa et al., 2007). These observations suggested 
that it is likely that the sporeamicin PKS would generate 6-deoxyerythronolide B, the 
aglycone intermediate of the erythromycin biosynthetic pathway. After checking the 
genes surrounding the sporeamicin BGC, no other gene that is part of the cluster 
encodes an oxidative enzyme that might be responsible for sporeamicin production. 
 
Figure 6.8: Organisation of the sporeamicin A and erythromycin BGCs. 
135 
 
 
 
Figure 6.9: Multiple alignment of the ketoreductase (KR) domains of the 
erythromycin (ery) and sporeamicin A (spo) PKSs. White letters over red background 
represent full conservation of the residue across all sequences. Blue arrows indicate the 
residues from the active site of the domain. Note that the conserved asparagine residue 
at position 140 has been mutated to serine in both KR3 domains. This alignment was 
generated with the MUSCLE tool (Edgar, 2004) from the EMBL-EBI server (Li et al., 
2015) and displayed with ESPript 3.0 (Robert and Gouet, 2014).  
 
6.7 Disruption of sporeamicin A biosynthesis 
I proceeded to investigate the biosynthetic pathway of sporeamicin A in strain L53-18 
through mutational analysis and biotransformation experiments.  
136 
 
6.7.1 Mutant generation 
Disruption mutants in the sporeamicin PKS were generated by standard single-crossover 
methods. A 2.3 kb fragment from the centre of the spoAII (equivalent to eryAII) gene was 
amplified by PCR and cloned into the suicide vector pKC1132 (pOJ260 based) that 
carries the apramycin marker, as described in Chapter 2 (Bierman et al., 1992). The 
resulting plasmid, pEVK13, should accomplish the disruption of the target gene by single 
crossover homologous recombination of the cloned region and the sporeamicin PKS 
leading to insertion of the suicide vector into the chromosomal DNA. pEVK13 was 
introduced in strain L53-18 via intergeneric conjugation from E. coli ET12567/pUZ8002. 
Of the 12 ex-conjugants observed, nine of them formed white-grey colonies and three 
formed red colonies. This is a phenomenon unrelated to the mutation as the red variants 
represent a class of spontaneous pleiotropic mutants, as mentioned above (Cortés et 
al., 2002). Six of the ex-conjugants, two red and four white, were taken through for further 
analysis.  
6.7.2 Metabolite analysis of the PKS disrupted mutants 
The six selected isolates from section 6.7.1 were grown in the same seed and production 
media used previously for sporeamicin A production. After seven days of growth, 
samples of fermentation broth were extracted and analysed by LCMS. We observed that 
the production of sporeamicin A and erythromycin A was abolished in these strains. As 
expected, this confirms that that both sporeamicin A and erythromycin A share the same 
biosynthetic origin. 
To determine whether the mutants could be chemically complemented and gain more 
insights in the biosynthesis of sporeamicin A, they were fed with a sample of 
deoxyerythronolide B, the direct product of the erythromycin PKS, to yield a final 
concentration of 100 μM (Gaisser et al., 2000). Surprisingly, the production of 
sporeamicin A and erythromycin A was not restored, suggesting that the compound 
could not be either internalised or incorporated into the pathway. A likely explanation 
could be that the mutation had resulted in undesired polar effects. Insertional inactivation 
often affects the expression of the downstream genes in a cluster and this could be 
especially possible in this case since eryAI, eryAII, eryAIII, eryBII, eryCII, eryCIII, and 
eryG genes are primarily co-transcribed from a promoter upstream of eryAI (Reeves et 
al., 1999) and we suggest that the same is likely to happen in the sporeamicin cluster. If 
this is the case, then disruption of the transcriptional unit would affect the expression 
genes involved in the biosynthesis or attachment of both the L-mycarose (B genes) and 
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D-desosamine (C genes) deoxysugars (Figure 6.2). Such a transcriptional scenario 
would mean that exogenously added 6-deoxyerythronolide would not be further modified 
as observed. Therefore, further work is required to generate a mutant without undesired 
polar effects. Despite this, our experiment was successful in yielding a mutant lacking 
the ability to produce sporeamicin A or erythromycin A directly. 
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6.8 Discussion 
Sporeamicin A had previously been reported as an erythromycin-like macrolide antibiotic 
produced by S. sp. L53-18 with improved clinical properties with respect to erythromycin 
(Morishita et al., 1992). Also, the structural differences between sporeamicin A and 
erythromycin suggested that the biosynthetic enzymes for producing sporeamicin A 
might have altered substrate specificity that would make them valuable for the 
bioengineering of new analogues of erythromycin. Therefore, it was of great interest to 
us to characterise the biosynthesis of sporeamicin A. After following the growth 
conditions published for the production of sporeamicin A by strain L53-18 we confirmed 
its production. However, we were surprised by the finding that erythromycin A was 
actually the main metabolite produced in this experiment. Following this discrepancy, 
which had not been mentioned before in the literature (Yaginuma et al., 1992), we 
focused our efforts on a genomic investigation to gain further insight into the biosynthesis 
of sporeamicin A. 
Genome sequencing of strain L53-18 identified an erythromycin-like BGC (spo BGC) 
that we presumed would be responsible for the biosynthesis sporeamicin A. Comparative 
bioinformatics analysis revealed that the spo BGC is essentially identical to the BGC for 
production of erythromycin A in S. erythraea. Based on in silico analysis there was no 
evidence to support that this cluster would produce an aglycone scaffold different to the 
one that leads to erythromycin A. We also examined the sequence flanking the spo BGC 
and no genes were present that would indicate expression of an oxidative enzyme for 
the conversion of erythromycin A into sporeamicin A. In fact, there was no obvious 
difference at the genome level in these flanking regions – this strongly suggested that 
any gene product responsible for the production of sporeamicin A from erythromycin A 
must be encoded somewhere else in the genome. The absence of any other compatible 
BGC in the genome indicated that both sporeamicin A and erythromycin A should come 
from the same (spo) BGC. 
In accordance with this hypothesis insertional disruption of the spo PKS abolished the 
production of both sporeamicin A and erythromycin A. Whilst this confirmed their 
common biosynthetic origin, it was unclear whether sporeamicin A derives from 
erythromycin A or a common intermediate, and how this modification is introduced. The 
exogenous addition of 6-deoxyerythronolide B, the first product of the erythromycin PKS, 
to growing cultures of the spo PKS mutant failed to initiate biosynthesis of erythromycin 
A, although this is probably due to a polar effect on downstream genes which mean the 
strain can no longer make or attach the deoxysugars L-mycarose (B genes) and D-
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desosamine (C genes) (Staunton and Wilkinson, 1997). Further experiments will aim to 
construct a mutant without polar effects.  
Finally, there is an opportunity to TAR clone the sporeamicin A BGC and transfer it to a 
heterologous host ideal for scale up, such as the S. erythraea superhost described earlier 
in Chapter 3. This might enable the isolation of sporeamicin A if the PKS has a subtle 
difference that we cannot detect, or it will allow us to further investigate how other 
modifications occur to the chemical structure.  
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7 Discussion 
The focus of this thesis project was to investigate the biosynthetic potential of the 
Saccharopolyspora KY strains isolated from Kenyan fungus-farming Tetraponera plant 
ants. Throughout the project a tripartite exploration of genomic, metabolomic and 
bioassay-guided approaches was exploited. Based on my investigations four major 
themes were developed: 
1. Activation of the kyamicin BGC and characterisation of its product  
2. Engineering of a synthetic platform for the expression of type B lantibiotics 
3. Isolation and structural determination of the new pseudo-peptide EV60 produced 
only in minimal media 
4. Investigation of the biosynthesis of sporeamicin and how it differs from 
erythromycin 
 
7.1 Kyamicin and platform for expression of type B lantibiotics 
The external microbiome of the Tetraponera ant cuticles is heterogeneous and 
dominated mainly by proteobacteria and firmicutes. Actinobacteria make up only a small 
percentage of the microbiome and that was the intriguing point for the beginning of this 
research based on the three Saccharopolyspora sp. strains: KY3, KY7 and KY21 (Seipke 
et al., 2013). This finding was particularly interesting given that Saccharopolyspora is a 
rare genus that contains strains which are prolific producers of important anti-infective 
agents.  
I set out to the study this rare genus from this underexploited ecological niche, firstly 
using a genomic-led approach.  The three genomes were found to be highly similar and 
encode approximately 23 BGCs with very significant overlap. As described, all three 
encoded a BGC with identical architecture, for a cinnamycin-like type lanthipeptide that 
became the focus of the genomic-led investigation. The fact that three different strains, 
sampled from two different locations, possess clusters for the same antibiotic suggests 
that either these compounds, or a closely linked trait, confer an advantage in this 
environment, or that the ants are selecting them for these traits. 
I reported the genomics-directed discovery of kyamicin. Kyamicin is a new member of 
the type B lantibiotic family, which includes cinnamycin and duramycin. As discussed in 
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this study, this is a potentially valuable finding since lantibiotics are a family of NPs with 
important activities as antibiotics, inhibitors of viral entry or even therapeutics for cystic 
fibrosis (Willey and Van Der Donk, 2007, An et al., 2018).  
The activation of the kyamicin BGC in the native host and heterologously was crucial to 
examine the potential for cross species activation of similar BGCs and worked as a proof 
of concept for this work. This led to the engineering of a type B lantibiotics platform that 
allowed for the expression of the duramycin and the cinnamycin B clusters, as described 
in chapter 4. The ability to generate analogues of cinnamycin-like type B lantibiotics with 
modified properties is of great importance and value, given the significant potential of 
such NPs in numerous and demanding therapeutic contexts.  
Expanding the application of this platform will be the focus of future research. The work 
described in this study provides a basis for the identification of additional natural 
lantibiotics, whose biosynthesis is cryptic in the host strain, and for the diversification of 
their chemical structures to generate new-to-nature molecules. Future lines of research 
include determining how many of the lantibiotic core peptide sequences uncovered by 
out bioinformatics analysis can be expressed using this platform, and how far can we 
stretch the system with unprecedented modifications of the core peptide sequences 
using a synthetic approach. If the synthetic lantibiotics deriving from this work can be 
made in useful quantities, and prove to have potentially useful properties, then they may 
be moved forward to preclinical assessment. One day they may even expand the toolbox 
of novel antimicrobials. 
7.2 Untargeted metabolomics  
After following an untargeted metabolomics approach, I reported the discovery of EV60, 
an NRPS-derived siderophore composed of 2,3-dihydroxybenzoic acid, D-threonine and 
N5-hydroxy-N5-acetyl-ornithine (stereochemistry to be determined).  
Parallel to our work, colleagues from Dr Andrew Truman’s group were working with the 
strain Actinomadura atramentaria DSM43919. While investigating the biosynthetic 
pathway of the matlystatins, metalloproteinase inhibitors produced by the strain and 
reported in previous work (Leipoldt et al., 2017), they made a peculiar observation. 
During the course of a series of nucleophile feeding experiments, they observed intense 
phenotypic changes. Subsequent metabolomics analysis revealed the production of 
several new peaks that could be related to each other by metabolic networking analysis. 
The further purification and structural elucidation of four of these compounds revealed a 
pseudo-tripeptide scaffold identical to EV60 but carrying several additional post-NRPS 
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modifications. Unfortunately, A. atramentaria DSM43919 is not genetically tractable. For 
that reason, we passed onto them the strain KY21 in order to study the biosynthesis of 
this new family of molecules. 
7.3 Bioassay-guided fractionation 
Bioassay-guided fractionation proved less effective for us in identifying and isolating an 
antifungal compound that was suggested from overlay bioassays.  Our efforts towards 
scaling up the production of this compound were not successful.  Nevertheless, it was a 
potentially valuable finding that will be investigated further in the future. Isolating new 
antifungal molecules is of great significance since there is an urgent need for antifungal 
agents. The number of NPs available to treat life-threatening, invasive fungal infections 
available is significantly smaller than the ones with antibacterial activity (Roemer and 
Krysan, 2014).  Even though the field of antifungal discovery has not been completely 
static, since early last century only three classes of antifungal drugs have been 
developed (Krysan, 2017). Those are the polyenes such as amphotericin B (Herbrecht 
et al., 2002), the azoles such as fluconazole (Goodman et al., 1992), and the 
echinocandins such as micafungin (Pfaller et al., 2008). For these reasons, it is of 
absolute importance to investigate a potential new antifungal agent, deriving from the 
underexploited environmental niche of the Tetraponera ants. 
7.4 Sporeamicin 
The genomic-led approach for investigating the biosynthesis of sporeamicin gave 
unclear results. Next steps will include exogenously feeding the mutant strain described 
in chapter 6 with erythromycin and monitoring the production results.  The most probable 
scenario is that after providing erythromycin, some of it will be biotransformed to 
sporeamicin, supporting our theory that the difference between the two is the result of a 
post-PKS enzymatic modification. Other approaches we can employ in the future are to 
try deleting the whole BGC and/or transferring the BGC into a heterologous host such 
as the Saccharopolyspora superhost described in chapter 3. In the second scenario, the 
strain carrying just the erythromycin-like spo BGC, should produce only erythromycin if 
our hypothesis that the gene responsible for sporeamicin formation is encoded outside 
of the spo BGC. 
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7.5 Conclusions 
Based on the experience from this work some broader comments can be made about 
the three main approaches utilised for NP discovery. Firstly, the genomic-led approach 
usually starts from a point of many different BGCs that are predicted to encode for a 
variety of NPs, immediately offering many targets to follow. Importantly, it gives a full 
picture of the biosynthetic capacity of the strain, revealing the ability for NPs that might 
be considered silent or cryptic by the other approaches. This then allows for genetic 
strategies for the activation of cryptic BGCs, for example by the artificial expression of 
positive activators, or by heterologous expression, as demonstrated in this thesis. 
Usually, the re-discovery problem can be avoided by excluding BGCs that encode known 
products. Furthermore, since predictions are based on known BGCs, this can bias efforts 
towards the investigation of different variations of known compounds. This could 
potentially limit the discovery of compounds arising from novel genetic architecture not 
identified with BGC prediction tools, which would be likely to encode compounds with 
different structures and/or activities. This issue can be overcome by the design of 
bespoke scripts to find genes predicted to be responsible for the synthesis a compound 
of interest. As BGC prediction tools advance this problem may become less of an issue.  
Alternatively, the traditional bioassay-guided isolation of NPs ensures that efforts are 
focused on compounds with the desired bioactivities, which is not guaranteed by the 
other two approaches discussed here. When utilising the bioassay-guided approach it is 
important to investigate as many different culture media as possible to avoid missing 
compounds that are only expressed in certain environmental conditions. Likewise, a 
number of different bioindicator strains should be used so that all potential bioactivities 
of interest are covered. However, as mentioned previously, the major drawback of this 
method is the re-discovery of known compounds. 
Untargeted metabolomic approaches circumvents the potential biases of the approaches 
above, by considering all metabolites regardless of bioactivity or putative BGCs. As with 
the bioassay-guided approach, it is important to utilise a wide range of different media to 
try and cover the full metabolomic capacity of the strain of interest. It is also important to 
carefully check data to exclude m/z peaks that are just in the noise or arise from media 
components, and to consider all possible adducts that might be observed. Although 
modern UHPLC-HRMS techniques have very high levels of accuracy and sensitivity, it 
is important to bear in mind that the size and chemical properties of a molecule can affect 
their detection by MS. One other consideration for this approach is that the identification 
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of a NP for an m/z of interest can be challenging, mainly due to limitations in the available 
MS databases. The latest addition to untargeted metabolomics is metabolic networking, 
which will certainly help advance this approach, although again it can be limited by 
current m/z databases, which are still not sophisticated enough to cover the plethora of 
metabolic data available. 
Whilst it is clear these three approaches can work together and complement each other, 
matching a NP identified by bioactivity or mass to a BGC is not straightforward. This is 
especially true if mutational experiments in the producing organism are challenging, such 
as in strains that are not genetically tractable. In many cases, heterologous expression 
of the putative BGC is necessary to confirm it encodes a particular NP and this can be a 
lengthy process. 
To tackle the rising spectre of a post-antibiotic era, it is clear that we must use all the 
tools at our disposal in order to discover novel NPs more efficiently. 
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Appendix 1 
Primer Sequence 5'-3' 
16S_forw AGAGTTTGATCATGGCTCAG 
16S_rev TACGGTTACCTTGTTACGACTT 
eryAf CCAAGCTTCGGGAGGTCTACTGCTCGT 
eryAr CGGAATTCGAGCAACTTCCAGTCGGTGT 
eryAII_Int1a
_forw  
ACTCGACTCGCTCAACGC 
eryAII_Int1b
_forw  
TGAACGGCCAGTCCTACA 
eryAII_Int2a
_forw  
GATGGCCCTGCGCAAGCGCCT 
eryAII_Int2b
_forw 
GCAGCTGCTGGCCGGTGAGG 
eryAII_Int3a
_rev 
AGCTCGTCGGCGTGCAACGACC 
eryAII_Int3b
_rev 
AATCCCAGTCGATGTGCG 
eryAII_Int4a
_for 
GATTTCGACCCGGGCTTCTT 
eryAII_Int4b
_for 
GTCTTCGTCGGCATGAACGG 
eryAII_Int4c
_rv 
AAGTCGACGAAGGTGTACGG 
ermE-
int_forw 
AACGCTACGAGTCGATGGTC 
ermE-int_rev ATTCCTCTCGACCAACAGGC 
cinAdelF ATGATCCGAACGCACACCGACATCCAGGAGGAGATCATGATTCC
GGGGATCCGTCGACC  
cinAdelR CGGCGAGCCCGGAGGCTCACCGCGTCGATGCTCAGCTCATGTA
GGCTGGAGCTGCTTC 
chkapraFout AGATGATCGAGGATGCCAGG 
chkapraFin1 CGGATGCAGGAAGATCAACG 
chkapraFin2 GAGAAGTACCTGCCCATCGA 
chkapraR GCCCGTAGAGATTGGCGAT 
pGP9chkF GACGATGACGACGACCACC 
pGP9chkR TGGATCTATCAACAGGAGTCCA 
RILint GTTCCACGAGCGGTTCTG 
deltaCinAse
qF 
GGCCGAGCGCTCGTGGAGTTG 
deltaCinAse
qR 
GGGCGGCCAGATCGAGTGCTC 
pSET152 F GGCCGAGCGCTCGTGGAGTTG 
pSET152 R AAATACCGCACAGATGCGTAAG 
kyaseqF1 GACCTCCAGCGCCACCTGCAC 
kyaseqR1 GTCATGGTGATCTCCTTCGTC 
kyaseqF2 ATGCCGGTGCCGCAGATCGTC 
kyaseqR2 CCCGTGCAGCAGGTCCAGGTG 
kyaseqF3 CGCACCGGTGCGTTCGCCGAC 
165 
 
kyaseqR3 GATGGACTCCAGGTGCTCCTG 
kyaseqR4 GTAGGCGAGGTAGTCGTCCTC 
deltaCinXse
qF 
CCCGCCGCGACCGTGAGCACC 
deltaCinXse
qR 
CGATCGCGGGTGCGTCCTCGG 
152seqF      
         
 TAATGCAGCTGGCACGACAGG 
cinAcompF  
         
GGCGCGCATATGTCCGACACCATTCTTCG 
cinAcompR  
       
 GCCGCGTCTAGATCACTTGGTCGAGCCGTCGCAC 
533F GTGCCAGCGCCGCGGTAA 
1492R CGGTTACCTTGTTACGACTT 
kyaAdelF ATGATCCGAACGCACACCGACATCCAGGAGGAGATCATGATTCC
GGGGATCCGTCGACC  
kyaAdelR CGGCGAGCCCGGAGGCTCACCGCGTCGATGCTCAGCTCATGTA
GGCTGGAGCTGCTTC 
deltaKyaAse
qF 
GGCCGAGCGCTCGTGGAGTTG 
deltaKyaAse
qR 
GGGCGGCCAGATCGAGTGCTC 
cinAcompF GGCGCGCATATGTCCGACACCATTCTTCG 
cinAcompR GCCGCGTCTAGATCACTTGGTCGAGCCGTCGCAC 
KY3smNdeI-
F 
GCGGAATTCCGAAGCCGCGGATCTCCTGCCGTGG 
KY3smStuI-
R 
GCGGGTACCTTTAAAAGGCCTCGTTGGCCGCGATCCCCTTGG 
KY3lgStuI-F GCGAGGCCTAGCATCGACGCGGTGAGCCTCC 
KY3lgNdeI-
R2 
CCGATAGCTGTTCGGCGGGTACCAC 
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Appendix 2 
Supplementary Figure 1. 1H NMR spectrum (DMSO, 400 MHz) of EV60. 
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Supplementary Figure 2. 13C NMR spectrum (DMSO, 100 MHz) of EV60. 
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Supplementary Figure 3. COSY NMR spectrum (DMSO, 100 MHz) of EV60 
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Supplementary Figure 4. HMBC NMR spectrum (DMSO, 100 MHz) of EV60. 
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Supplementary Figure 5. HSQC NMR spectrum (DMSO, 100 MHz) of EV60.  
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Supplementary Table 1: 1H NMR chemical shift ppm table. 
 EV60 
δ in ppm 
number 1H (J in Hz) 13C 
1 - 167.9 
2 - 116.7 
3 - 148.0 
4 - 146.0 
5 6.93, dd (7.8, 1.4) 118.5 
6 6.71, dd (8.0, 7.8) 118.2 
7 7.37, dd (8.0, 1.4) 118.8 
2’-NH 8.59, d (8.0) - 
1’ - 169.8 
2’ 4.43, dd (7.9, 5.1) 58.9 
3’ 4.05, m 66.6 
4’ 1.12, d (6.3) 19.9 
2’’-NH 8.18, d (7.5) - 
1’’ - 173.4 
2’’ 4.20, m 52.0 
3’’ 1.51-1.77, m 28.5 
4’’ 1.51-1.77, m 23.1 
5’’ 3.47, m 46.6 
1’’’ - 170.3 
2’’’ 1.96, s 20.3 
 
Analytical data for EV60 
UV/Vis (MeOH): λmax (log ε) = 205 (3.53), 249 (2.72), 313 (2.35) nm. 
[α]D
20 =  ‐10.93 
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Supplementary Figure 6. HSQC NMR spectrum (DMSO, 800 MHz) of kyamicin. 
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Supplementary Figure 7. TOCSY NMR spectrum (DMSO, 800 MHz) of kyamicin. 
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Supplementary Figure 8. NOESY NMR spectrum (DMSO, 800 MHz) of kyamicin. 
 
 
 
 
 
